



Australian Government

**Community
Grants Hub**
Improving your grant experience



Final Report Template

Grant Activity Details

Organisation Name:	National Centre for Clinical Research on Emerging Drugs (NCCRED)	Grant Program Name:	Alcohol, Tobacco and Other Drugs Program
Grant Activity Title:	National Centre for Clinical Research on Emerging Drugs	Grant Activity ID:	4-EH8ULD4
Grant Activity Start Date:	1 July 2020	Grant Activity End Date:	30 June 2024
Total Grant Agreement Funding:	\$1,870,000.00	Final Report Submission Due Date:	31 August 2024



1. Executive Summary

Objectives

The objectives of the grant opportunity are:

- to develop, implement and disseminate innovative and effective evidence-based treatment interventions that can be applied to the use of methamphetamine (ice) in the first instance, and then to new and emerging substances;
- to develop and implement a system that allows for a rapid, flexible and collaborative response to emerging substances that are having prevalent, persistent and harmful health and community impacts;
- to leverage evidence-based intervention methodologies to develop and equip the health and medical research workforce.

Approach

Australia has the highest rate of methamphetamine use disorder (MAUD) in the world, and there are no effective treatments available. To address this, NCCRED was established as part of the Australian Government's National Ice Action Strategy in 2017 with the intention to bring together clinicians and researchers to detect and respond to emerging drugs of concern. NCCRED places people who use drugs, their friends, families, carers and communities at the core of its activities. To achieve its objectives, NCCRED implemented three key strategic actions from the required activities in order to structure its deliverables – **Collaborate, Generate and Translate**. Using these strategic actions as a framework, NCCRED aims to **collaborate** to build capacity for clinical research into emerging drugs, to **generate** new evidence-based knowledge, and to **translate** research into effective clinical practice.

Key Results and Insights

Collaborate

NCCRED collaborated with key stakeholders within the AOD sector to build adaptive clinical networks. NCCRED successfully proved the feasibility of a National Clinical Research Network (NCRN) by collaborating with them to develop a category 1 research funding application (NHMRC) for a multi-centre randomized control trial (RCT) focused on outcomes for people with MAUD; awarded \$2,175,000.00 in funding. Furthermore, after consultation with national stakeholders, NCCRED implemented two digital components of the PRN: The Know Community and [The Know](#) public website. The Know Community is a closed membership platform that enables members from all jurisdictions to exchange information about emerging drugs, including those impacting rural and remote areas (**Appendix 1**). [The Know](#) public website was created to provide a national publicly accessible resource that provides an overview of emerging drug alert information across Australia. Together, these digital components facilitate collaboration and knowledge exchange to reduce drug-related harm nationally.

Generate

Through a comprehensive strategy involving collaborative clinical research, seed funding, scholarships, and mentorships, NCCRED has developed effective interventions directed towards high-quality research on methamphetamine and other emerging drugs of concern. Over the course of this contract period, NCCRED has led 15, supported 7, and funded 27 clinical trials/clinical research projects. Among the key initiatives is the open-label trial and a multicentre randomised controlled trial of lisdexamfetamine for the treatment of acute methamphetamine withdrawal, which aims to provide effective pharmacological solutions for this challenging condition. Another key initiative is NCCRED's GHB related program of work, including research into GHB-related overdose, dependence, and withdrawal. For a running register NCCRED's of clinical research see **Appendix 2**.



Translate

NCCRED has leveraged clinical networks to implement and disseminate evidence-based models of best practice and guidelines, advancing the AOD workforce's capabilities in addressing the impacts of methamphetamine and emerging drugs. This effort includes the development of the Methamphetamine Clinical Guide to Primary Care, created in collaboration with the Royal Australian College of General Practitioners (RACGP); the development of the AOD Telephone Counselling Toolkit, conducted with the Alcohol and Drug Information Services (ADIS); and multiple training sessions, including one after consultation with non-government organisation (NGOs) peaks focused on building clinical research capacity for clinicians (**Appendices 3 and 4**). Additionally, NCCRED produced the VAN (Video Abstracts by NCCRED) series to present research findings in a concise, accessible format, with seven VANs released between March 2022 and March 2024. The VANs are available on the [NCCRED website](#) and [YouTube channel](#), (**Appendix 4**).

Implications for Current and Future Research

Ongoing research into scalable treatment options and culturally sensitive approaches will be vital for addressing the complex challenges of methamphetamine and emerging drugs. Disseminating research outputs through publications, presentations, and digital platforms will ensure that new knowledge is effectively communicated and applied in clinical settings.

Advancing Methamphetamine Treatment:

New pharmacological treatments for methamphetamine use disorder should continue to be conducted to evaluate new pharmacological treatments for acute methamphetamine withdrawal and dependence. NCCRED will continue to meet this priority by trialling the efficacy of oral lisdexamfetamine for withdrawal and assessing the feasibility of bupropion/naltrexone and ketamine-assisted psychotherapy for MAUD. These trials aim to provide valuable clinical insights into managing symptoms of MAUD.

Novel Approaches for GHB Withdrawal:

There are no approved pharmacotherapies to treat GHB withdrawal. NCCRED plans to develop a project to test whether Baclofen, frequently used to treat alcohol withdrawal, could be used to treat GHB withdrawal. There is little to no data on the use of Baclofen specifically for GHB withdrawal, despite it being used clinically. By testing the feasibility of Baclofen, NCCRED will build the evidence base for an effective medication for GHB withdrawal, potentially expanding treatment options for people who use GHB.

Enhanced Knowledge Translation:

Developing and disseminating e-learning modules and video abstracts can facilitate the translation of clinical research into actionable resources for practitioners and the public. These tools aim to enhance understanding and application of new treatment options for methamphetamine and emerging drugs. NCCRED plans to continue to develop and disseminate these translational products which have proven to be popular research outputs.

Innovative Digital tools for Treatment Support:

The continued development and integration of digital tools like NCCREDs S-check app are essential for promoting treatment-seeking behaviour and supporting behaviour change. Furthermore, NCCRED will pilot an internet-based cognitive behavioural therapy (ICBT) for methamphetamine dependence which presents an opportunity to evaluate and refine online therapeutic interventions. These tools could provide valuable insights into the feasibility and efficacy of digital treatment options, potentially leading to broader implementation in clinical settings.

Strengthening the Prompt Response Network:

Enhancing systems like the PRN will be vital for improving responses to emerging drug issues. Research from these systems can provide critical data on drug prevalence and toxicity, which is essential for refining clinical practices and public health strategies. NCCRED will continue to develop the PRN by devising additional data collection and sharing systems while also researching and evaluating the PRN's impact.



2. Report Against Activity Work Plan Deliverables


Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
1. Collaborate						
1.a. Build on and extend the National Clinical Research Network (NCRN)	The methamphetamine and emerging drugs clinical research network working group (WG) was launched in 2018 to support the development of a methamphetamine and emerging drugs NCRN. The WG was established to guide the clinical research strategy of the Centre through its funding programs as well as the development of a NCRN. Prior to this contract, the WG had: <ul style="list-style-type: none"> acted as the expert advisory panel for the NCCRED Clinical Research Priority Setting Study then, as the expert panel ranked priorities 	The WG successfully: <ul style="list-style-type: none"> Reviewed the revised WG Terms of Reference. Reviewed the top 10 Round 4 seed funding grant applications and recommended 6 applications to the NCCRED Board for funding. Reviewed 6 Clinical Research Scholarship applications and recommended 3 applications to the NCCRED Board for funding. Due to a competing priority one successful applicant had to decline the offer so two Scholars were appointed. 	The WGs independent reviews of round 4 Seed funding applications and clinical research Scholarship applications allowed NCCRED to award \$760,840.48 in this reporting period. Successful applications are listed on the NCCRED website . The impact of the clinical research funding program can be in the NCCRED Clinical Research Funding Program report published in June 2024. In this reporting period, NCCRED, along with the NCRN, completed a pilot study based on a planned randomised controlled trial		This activity was achieved.	This activity was evaluated on the engagement of the WG with the review of seed funding and scholarship applications and also the outcome of a demonstration project, as suggested by the future direction report produced by the Chrysalis Advisory. 23 applications were received, three were deemed ineligible by the Chair for being out of scope. The 20 applications were divided up among the WG members and reviewed and scored by the WG with the top 10 applications then reviewed by the WG as a group 11 May 2021. The WG agreed that six applications should be funded




Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>through a consensus process</p> <ul style="list-style-type: none"> ▪ reviewed NCCRED Clinical Research Funding applications including: <ul style="list-style-type: none"> ○ six Clinical Research Capacity Building Grant applications, and recommended of three of these for funding ○ 50 Clinical Research Seed Funding applications, and recommended 15 of these for funding, across three different funding rounds ○ seven Clinical Research Fellowship applications, and recommended appointment of three NCCRED Clinical Research Fellows ▪ Provided recommendations for a scoping paper and 	<p>An online national stakeholder meeting (facilitated by Chrysalis Advisory) with the WG and other stakeholders (32 people), was conducted on 2nd November 2020 to discuss moving towards a national clinical research network. Chrysalis Advisory produced a Future Directions report which recommended a demonstration project to test the feasibility of a NCRN.</p>	<p>which was then developed into a category 1 (NHMRC) competitive research funding applications in collaboration with the NCRN for a multi-centre randomized control trial (RCT) focused on outcomes for people with methamphetamine use disorder (MAUD).</p>			<p>and a total of \$459,950.78 was awarded out of a requested \$1,429,683.29. This process involved significant and successful engagement from the WG.</p> <p>NCCRED successfully developed a demonstration project from results of a single site pilot study into a category 1 (NHMRC) competitive research funding application for a multi-centre RCT involving members of the NCRN from multiple jurisdictions.</p> <p>The likelihood of an NHMRC grant being awarded for a clinical trial in 2023 was 10.3%. Historically, successful grants often include involvement from a broad range of stakeholders from different jurisdictions, thus the inclusion of an NCRN, such as the one</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>consultative process towards the development of a NCRN.</p> <p>The WG was also to oversee the final clinical research funding rounds as well as the completion of the program.</p>					<p>utilised for this demonstration project, is likely to significantly increase the chances of a successful NHMRC grant application.</p> <p>This grant was successful in its funding application and was awarded \$2,175,000.00 for a clinical trial cohort study, proving strong support for the feasibility of an NCRN.</p>
1.b. Develop and implement a system to promptly detect and respond to new and emerging drugs of concern	<p>The vision of the Prompt Response Network was created in line with a website similar to the 'ProMed' website (promedmail.org) currently used for the notification of infectious diseases. In 2018-19, under the stewardship of NCCRED, a national PRN was developed. An outline for the PRN was prepared, and a summary of the aims, expected outcomes, and proposed model and reach has been established.</p>	<p>NCCRED finalised the national consultations which begun in the period 2019-2020 and were delayed due to COVID-19. The national consultation process underscored the need for both a closed network and consumer-facing messaging, showing strong support across jurisdictions.</p> <p>Stakeholder mapping consultations outlined the requirements for the platform and helped drive</p>	<p>National consultations were attended by 30 people was held on the 2nd of September 2020. Membership for the "closed" 'The Know Community' and "open" reference groups formalised in March 2021.</p> <p>The development of The Know Community digital platform included:</p> <ul style="list-style-type: none"> ▪ PRN Protocol ▪ Mapping of existing networks and processes 		<p>Rationale for amber status: Development of the Minimal Viable Product version of the National Signal Register was completed. The progression of this was delayed due to IT assurance processes and data sharing agreements. This work will continue</p>	<p>This activity was evaluated by engagement and reach within the AOD sector. This includes the number of members onboarded to the closed digital platform, website visits and continued engagement by jurisdictional members at meetings.</p> <p>The Know Community website was visited by 4,974 people and achieved and 34,000 page views.</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>Prior to this contract, NCCRED consulted widely across the AOD sector in all States and Territories. Representatives from government, forensics, public health, ambulance services, and consumer organizations participated in these state-level meetings.</p>	<p>the development direction for the platform. Stakeholder mapping consultations platform took place between 20th July and 13th October 2021 with 16 key stakeholders across all jurisdictions.</p> <p>The development of the closed PRN digital platform was completed.</p> <p>The PRN facilitates ongoing meetings between select stakeholder groups to facilitate a national health-led approach to emerging drugs.</p> <p>A co-design process together with external consultants and the PRN Peer Advisory Group to develop a system to feed anecdotal signals into the PRN was undertaken.</p>	<ul style="list-style-type: none"> ▪ Identification of PRN opportunities and functional components ▪ Identification of technical solutions ▪ Completion of PRN Brand Discovery <p>The Know Community launched 6 December 2022. As of June 2024, there have been 103 alerts from community and government organisations have been republished on The Know Community website</p> <p>The Know public website was launched in July 2023 as a platform to provide a centralised, public facing source of reliable and actionable information on emerging drugs. As of June 2024, 25 jurisdictional drug alerts have been published on the website.</p>		<p>into the next contract.</p>	<p>The Know public website has received 3,231 visitors, and 11,000 page views.</p> <ul style="list-style-type: none"> ▪ National PRN group quarterly meetings were held 8 times in total. ▪ 2022 (May [53 attendees], Aug [92 attendees], Nov [55 attendees]), ▪ 2023 (Feb [63 attendees], May [54 attendees], Aug), ▪ 2024 (May [66 attendees]) <p>With regards to The Know Community closed digital platform, over 260 members have been onboarded to the platform and there have been approximately 202 posts and 189 comments. There is membership from all jurisdictions as shown in Appendix 1.</p> <p>This reach enables The Know community members to discuss and share information about emerging drugs, including those affecting rural</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
			<p>National PRN group quarterly meetings were held 8 times in total;</p> <ul style="list-style-type: none"> ▪ 3x in 2022 (May, Aug, Nov), ▪ 3x in 2023 (Feb, May, Aug), ▪ 1x in 2024 (May) <p>A research priority setting study was submitted and approved by UNSW Ethics to conduct a qualitative thematic analysis, brief literature review and ascertain key themes. Results obtained, informed the PRN evaluation plan research agenda as has our ongoing consultation with our PRN advisory. This work is contracted to continue under the new contract.</p>			<p>and remote areas, in a closed setting. For example, the increased reports of nitazenes discussed within the Know Community prompted in NCCRED to create a special edition of the DARIA webinar series and an emerging drug briefing on the topic.</p> <p>During this period, NCCRED observed challenges in inter-departmental communication within states and across jurisdictions. Delays in developing the national signal register were due to difficulties in agreeing on information inclusion and navigating data sharing processes. Despite these setbacks, work has continued under the new contract and is expected to be completed within the contract period.</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
<p>Testimonials provided to NCCRED about the NCCRED PRN jurisdictional meetings:</p> <p><i>“It’s another example of how useful the network can be... the information collated from each jurisdiction can be circulated around the country with groups being aware of what’s happening nationally and locally.”</i> (Assistant Director Science & Support at Forensic Science SA)</p> <p><i>“The PRN Jurisdictional Lead meeting has been a great way to hear about the work that is progressing in this space nationally, and also by each jurisdiction.”</i> (Senior Policy Officer, Rural and State-wide Strategy, Planning and Partnerships Team, Queensland Health)</p> <p><i>“I am really happy with the level of engagement (meeting monthly, content including updates and component development) and I appreciate the level of interaction and consultation and I don’t feel it’s onerous for the importance of the project.”</i> (Co-Head of the NSW Poisons Information Centre)</p>						
1.c. Organise an annual national symposium	The annual national clinical research symposium is a key platform for NCCRED, its collaborators and funding recipients to share their translational products, research outcomes and findings addressing clinical developments within the substance use disorder field	<p>NCCRED successfully delivered four annual national symposia. Due to COVID-19 from 2020 the symposia were held online; in 2022 a hybrid approach was successfully adopted with both virtual and online attendees.</p> <p>Presentations, abstracts and programs for all symposia are available on the NCCRED website.</p>	<ul style="list-style-type: none"> 2020: Innovations in therapeutic practice 2021: Improving Outcomes: Interventions, Networks & Pharmacotherapies 2022: Transforming healthcare responses to methamphetamine and emerging drugs 2023: Bridging knowledge and practice for methamphetamine and emerging drugs 		This activity was achieved	<p>This activity was evaluated on the number of attendees, with the aim of increasing numbers each year.</p> <ul style="list-style-type: none"> 2020: 106 attendees. 2021: 109 attendees. 2022: 251 attendees (71 in person, 180 attendees online). 2023: 130 attendees (107 in person, 23 online). <p>The 2022 symposium was the most successful in terms of attendance, attributable to the hybrid approach. Attendance in 2023 reduced, due in part to staff turnover and therefore less support available for symposia planning and</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
						marketing. Post-event evaluation questionnaires (used in 2019) will be re-instated from 2024 onwards to gain insights to improve attendance rates moving forward. Key team members are now in place and have developed a symposia planning and marketing strategy to ensure attendance rates increase each year.
2. Generate						
2.a. Support, lead or establish clinical trials and clinical research focussing on the development of scalable and cost-effective treatment options	NCCRED, consortium partners and the NCRN have successfully supported, lead, and established clinical trials which have generated new evidence-based knowledge that leads to improved treatment and health outcomes for people experiencing substance use disorder.	(1) Open-label trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal - ANZCTR: ACTRN12621000045819 (2) Multicentre randomised controlled trial of lisdexamfetamine for the treatment of acute methamphetamine withdrawal	Four competitive research funding applications successfully submitted in the reporting period: <ul style="list-style-type: none"> NHMRC RCT Cohort Studies; ARC Linkage Projects; New South Wales (NSW) Translational Research Grants Scheme; Canadian Institutes of Health Research(CIHR) 		This activity was achieved.	Tasks (1,2 and 7) were evaluated by number of grant applications submitted (with the aim of one major application per year), establishment of clinical trials (ethics approval, trial registration) and associated research outputs driving positive outcomes within the AOD sector for people who use methamphetamine.



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>Prior to this contract, NCCRED developed a research priority setting study to determine the clinical research priorities of the AOD sector for the treatment of substance use disorders. The key priorities for methamphetamine were:</p> <ul style="list-style-type: none"> Overcoming barriers to intervention uptake (e.g. at time of crisis in emergency departments or primary health care) Pilot pharmacotherapy trials for adults seeking treatment Effective communication strategies for consumers on available treatments and the evidence-based options <p>The key priorities for emerging drugs were:</p> <ul style="list-style-type: none"> Fixed-site community-located drug checking / 	<p>(3) Research into social and cultural aspects of GHB use among LGBTQ Australians.</p> <p>(4) Identify factors associated with emergency department admission for complications due to GHB consumption</p> <p>(5) Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials - Prospero: CRD42021224850</p> <p>(6) Feasibility and efficacy of the S-Check App as a self-administered harm reduction and early intervention tool for those who use methamphetamine - ANZCTR: ACTRN12619000534189</p>	<p>For a running register of clinical research – see Appendix 2.</p> <p>For a list of published outputs – see Appendix 5.</p>			<p>NCCRED successfully applied for two research grants:</p> <ul style="list-style-type: none"> NHMRC RCT cohort study with 5 NCCRED staff as co-investigators (CIA Ezard) (see activity 1.a.) and Canadian Institutes of Health Research grant with two NCCRED staff as international co-investigators (CIA Jutras). <p>Tasks 3 and 4: Successfully completed two qualitative studies exploring experiences of GHB use among LGBTQ and heterosexual Australians which have informed a need for standard of care in GHB withdrawal and toxicity. NCCRED have developed a program of work which will result in building the evidence base for an effective medication for GHB withdrawal. This work is being</p>




Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>pill testing (connected to an early warning system)</p> <ul style="list-style-type: none"> ▪ Feasibility of social media and other creative opportunities to alert consumers and reduce harm ▪ GHB overdose and withdrawal management ▪ Shared information system –pooling and sharing of information – and assessing impact on reducing harm <p>NCCRED implemented these priorities in its clinical trial development (e.g. Pharmacotherapy trials for adults seeking treatment & GHB program of work), its clinical research funding program and the further development of the PRN.</p>	<p>(7) Randomised double-blind placebo-controlled study of lisdexamfetamine for the treatment of methamphetamine dependence - ANZCTR: ACTRN1261700065732</p> <p>(8) Prompt Response Network Australian Priority Research Study</p> <p>(9) Development of digital health intervention for methamphetamine</p>				<p>continued into the new contract.</p> <p>Task 5: Successfully published a systematic review and meta-analysis summarising the evidence regarding pharmacological treatments for methamphetamine withdrawal (See Appendix 5). This was the first systematic review and meta-analysis conducted since 2008 and highlighted the lack of research in recent years for treatments of methamphetamine withdrawal.</p> <p>Task 6: Successfully completed feasibility and efficacy clinical trial demonstrating positive outcomes for those using the S-Check app – outcomes published in peer-reviewed journal (See Appendix 5). NCCRED have commenced</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
						<p>work translating the outcomes of this study into a scalable e-intervention for people who use methamphetamine. This study has received ethics approval and will commence under the new contract.</p> <p>Task 8: The research priority setting study was submitted and approved by UNSW Ethics to conduct a qualitative thematic analysis, brief literature review and ascertain key themes. Results obtained, along with continued consultation will inform the PRN evaluation and research plan. This work is contracted to continue under the new contract. (see activity 1.b.).</p> <p>Task 9: iCBT program content successfully developed with consumers and clinicians, currently being developed into a web-based</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
						platform alongside research protocol development to evaluate the program. This work is contracted to continue under the new contract.
<p>Testimonial in response to: ‘An open-label trial of lisdexamfetamine for acute methamphetamine withdrawal. <i>“I’ve been shocked at how, how effective it has been in, yeah, just ... I just have no cravings. I feel completely normal. I’ve had an appetite. I’ve been socially active in here. I’ve been reading, which I, you know, haven’t done for a fairly long time, you know. Yeah. I’ve, yeah, it’s been awesome, to tell the truth.”</i> (Study participant)</p> <p>Impact of Freeman et al and Siefried et al presentations at APSAD Conference: <i>“Thank you so much for the updated info and materials... This will help us improve our existing policies for our patient” care and also handle GHB withdrawal in a prison setting better”</i> (Nurse Practitioner, Justice and Forensic Health Network)</p> <p>Testimonial in response to: Freeman et al ‘Playing at the edges, navigating sexual boundaries, and narrating sexual distress; Practices and perspectives of sexuality and gender diverse people who use GHB’ <i>“AIVL praises Freestone et al. for the ingenuity of their research that has shed light upon some of the lesser understood scenes associated with recreational drug use, and the role of harm reduction, peer networks and ever apparent need for education around overdose and BBV/STI risks surrounding chemsex.”</i> (AIVL)</p>						
2.b. Develop a Clinical Research Scholars Program to build research capacity through a seed funding research and training program	Prior to this contract, the first round of Seed Funding opened for competitive applications on 25 September 2018 and closed on 28 October 2018. Total grant funding awarded in Round 1 Seed Funding: \$196,137.50.	For this funding period NCCRED held the final seed funding round and two clinical research scholarship rounds, one aimed at Allied Health and nursing applicants, the other specifically for Aboriginal and Torres Strait Islander clinicians. The decision for	The WG recommended 6 projects for round 4 seed funding. This decision was ratified by the NCCRED Board on 17th of May 2021. The NCCRED Clinical Research Scholarship program (nursing & allied health stream) received 6		This activity was achieved.	Successful NCCRED Clinical Research Scholars and grant applications can be found on the NCCRED website . NCCRED received 23 applications for round 4 of the seed funding program. Total funding requested was \$1,429,683.29. The



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>The second round of Seed Funding applications opened on 18 January 2019 and closed on 15 April 2019. Total funding awarded in Round 2: \$381,982.83.</p> <p>The third round of Seed Funding applications opened on 15 May 2019 and closed on 15 August 2019. Total funding awarded in Round 3: \$636,690.50.</p> <p>Capacity Building Grants applications opened on 25 September 2018 and closed on 28 October 2018. Total funding awarded in Capacity Building Grants: \$304,000.00. Clinical research fellowship applications opened on the 15 May 2019 and closed on the 30 June 2019. Three</p>	<p>the Aboriginal and Torres Strait Islander specific application round was discussed following a presentation at NIDAC where a stakeholder engagement process with the Aboriginal and Torres Strait Islander Working Group and their networks was undertaken. The goal was to engage with clinicians interested in research and to promote the Clinical Research Scholarships.</p> <p>These scholarship rounds combined seed projects and scholarship funding to increase the project funding allocation.</p> <p>The WG recommended top applications to the NCCRED Board who ratified these decisions.</p>	<p>applications (4 male, 2 female). The WG recommended 3 scholars be awarded, though one applicant had to withdraw for personal reasons.</p> <p>The Aboriginal and Torres Strait Islander Scholarship program, as advised by the Aboriginal and Torres Strait Islander Working Group, was conducted in a two-stage process. Applicants submitted an expression of interest, who then, if successful, partnered with a mentor from the Aboriginal and Torres Strait Islander Working Group to work up a full application.</p> <p>1 application was received for the Aboriginal and Torres Strait Islander Scholarship clinician stream (male). This application was reviewed by the Aboriginal and Torres</p>			<p>breakdown of applicants from each state for Round 4 Seed Funding Grants was as follows:</p> <ul style="list-style-type: none"> ▪ 12 (52%) NSW ▪ 7 (30%) VIC ▪ 3 (13%) QLD ▪ 1 (4%) WA <p>Three applications were from NGOs or consumer groups that represent people who use illicit drugs, 6 were submitted from rural and regional areas.</p> <p>NCCRED received seven applications for the NCCRED Clinical Research Scholarship program. The total amount of funding requested was \$786,407. The breakdown of applications from each state was.</p> <ul style="list-style-type: none"> ▪ 3 Vic ▪ 2 NSW ▪ 1 QLD ▪ 1 SA



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	<p>NCCRED Clinical Research Fellowships were awarded.</p> <p>Majority of projects experienced delays due to Covid-19 pandemic, thus projects were extended into this funding period.</p>		<p>Strait Islander Working Group on who recommended the application be funded. This decision was ratified by the NCCRED Board.</p> <p>A Clinical Research Funding Program Report 2018 – 2023 was published in June 2024 which outlines the impacts of the program as a whole. For a full list of NCCRED funded clinical research see Appendix 2.</p>			<p>Of the three awarded applications 1 was from NSW, 1 from Vic and 1 from SA. Throughout the Clinical Research Funding Program, the majority of applications were from NSW and VIC. While this was expected, having a targeted round, in a similar fashion to the targeted Aboriginal and Torres Strait Islander Scholarship round, may have resulted in receiving a broader range of applications (attracting rural and remote applicants or those from different jurisdictions). (suggest saying that you plan to do this in the new contract to ensure a broader reach of the program).</p> <p>Nonetheless, a significant proportion of projects successfully involved multiple states and territories due to the requirement to include a</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
						<p>variety of stakeholders, demonstrating the success of the program.</p> <p>In total, \$2,745,861 was awarded to 24 capacity building and seed funding clinical research projects and six clinical research scholars. While rounds 1-3 of the seed funding grants, the NCCRED clinical research fellowships and capacity building grants were awarded in the previous contract, due to Covid-19, all projects were extended into the current reporting period.</p> <p>The Clinical Research Funding Program produced the following outputs:</p> <ul style="list-style-type: none"> ▪ 34 publications ▪ 138 presentations ▪ 1 policy change ▪ 17 clinical guides or practice changes ▪ 19 Media reports or releases



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
2.c. Develop and implement a multidisciplinary mentoring and training program	In the previous reporting period, NCCRED offered mentoring and partnership linkages between clinicians and researchers for the development of grant applications. This desired outcome of this was to build the clinical research capacity within the clinician workforce. This goal was continued into the current program of work for the extension of the clinical research funding program of work.	<p>NCCRED provided specialised clinical research support to multi-disciplinary clinical researchers as part of the Seed Funding and clinical research scholarship rounds, to facilitate their research capacity and value-add to existing clinical research.</p> <p>Additionally, NCCRED offered mentoring to students across multiple academic institutions.</p> <p>NCCRED linked NCCRED Clinical Research Scholarship recipients with specialised clinical research experts to assist in the outcomes of their projects.</p> <p>NCCRED held a clinical research training program specifically for NCCRED Clinical Research Scholarship recipients to</p>	<p>Three clinical research experts were identified and linked to the three clinical research scholars. These mentors were reimbursed for their time on the project. For a roll of mentors and mentees please see</p> <p>The clinical research training program for NCCRED Clinical Research Scholarship recipients included:</p> <ul style="list-style-type: none"> ▪ ICH-GCP training ▪ Biostatistics ▪ Australian research context ▪ Library resources <p>A running register of training and education sessions can be found at Appendix 4.</p> <p>In the reporting period, NCCRED staff successfully supervised:</p> <ul style="list-style-type: none"> ▪ Two PhD candidates. 		This activity was achieved.	<p>This activity was evaluated by the results of the Scholarship program (6 projects) and the final reports developed by the scholars. The Scholarship program collectively produced the following outputs across the three rounds:</p> <ul style="list-style-type: none"> ▪ 8 publications ▪ 34 presentations ▪ 2 clinical guides or practice changes ▪ 1 media report <p>NCCRED sought feedback about the Scholarship program from scholars as part of their final report submissions. These reports noted that the training and mentorship program positively impacted the results of their projects. Feedback about the mentors included that the supervision received was “integral during the initial rollout of the protocol” also that the guidance given</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
		assist with their scholarship project.	<ul style="list-style-type: none"> ▪ Three Medicine Honours student (UNSW) to completion (First Class). ▪ One Medicine Honours student (UNSW) to completion ▪ One ILP student. ▪ One year 2 Medicine student (University of Notre Dame) ▪ Two-year 4 Medicine students (UNSW) For a full list of students supervised and mentored see Appendix 6.			<p>around the “logistics of implementing the recreational drug intoxication protocol was invaluable”. The mentorship program was also said to have allowed dedicated time to develop skills. One recipient reflected that they appreciated time “to learn and understand the research processes and how they differ from clinical or administrative work.” Finally, NCCRED received feedback that the mentorship and training program also “gave me confidence to take a more assertive and independent approach with my component of the research (to make important decisions about the project’s design and overall direction).”</p> <p>NCCRED feels that activities relating to the Scholarship program were successful. Feedback from scholarship</p>




Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
						recipients highlighted that they developed knowledge of the research process, technical skills and confidence to carry out their projects. While outcomes of the mentorship and training program were positive, NCCRED endeavours to continually improve the structure of this program to enable more successful outcomes for those who receive NCCRED research mentorship in the future.
3. Translate						
3.a. Produce and disseminate guidelines, decision-aid tools and current models of best practice/clinical excellence via electronic platforms and	Prior to this contract, NCCRED produced a new clinical guide for the management of methamphetamine use disorder in primary care. These were adapted from guidance provided to general practitioners in South East Sydney on the Health Pathways network	NCCRED developed the Methamphetamine Clinical Guide to Primary Care with input from RACGP partners. NCCRED developed a video abstract series (VAN's) to facilitate short-format results reporting of NCCRED research,	The Methamphetamine Clinical Guide to Primary Care is available online and in print. For a running register of clinical guidelines and best practice models developed by NCCRED see Appendix 3 . Between March 2022 and March 2024 seven VANs		This activity was achieved.	This activity was evaluated by engagement with the Methamphetamine Clinical Guide to Primary Care and website analytics for the VANs available on the NCCRED website and YouTube channel . 290 print copies of the clinical guide have been requested



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
integration into training programs	<p>(with permission). Available in print form and online, and disseminated through newsletters, the clinical guide was expanded on, providing clinicians with screening tools, evidence-based management advice for treatment and withdrawal and directs clinicians and clients to useful resources, including details for all AOD intake teams nationally and State-specific AOD information services. For this contract, NCCRED planned to update this clinical guide and expand its collaboration efforts for input and reach out to colleagues from the planned to RACGP.</p> <p>NCCRED aimed to translate its led, funded and established clinical research into accessible outputs with a target audience of both</p>	accessible to a range of stakeholders.	<p>were developed. VAN's are available on the NCCRED website and the NCCRED YouTube channel.</p> <ul style="list-style-type: none"> ▪ GHB Cultures, Practices and Experiences Study – 29th March 2022 ▪ Pharmacotherapies for Methamphetamine Withdrawal – 11th July 2022 ▪ Lisdexamphetamine for the treatment of methamphetamine withdrawal: Safety and feasibility - the OLAM study – 6th February 2023 ▪ Strengthening first line telephone support for people who use Methamphetamine – 12th April 2023 ▪ The role of technology in therapy for methamphetamine use disorder (Fellowship 			<p>from all states and territories as well as international colleagues. While the requests for print copies have continued to come through, NCCRED could have utilised a prolonged dissemination plan in order to broaden the reach out this output.</p> <p>The VANs have collectively been viewed 20,318 times.</p> <ul style="list-style-type: none"> ▪ GHB Cultures, Practices and Experiences Study – 4,593 views ▪ Pharmacotherapies for Methamphetamine Withdrawal - 1,484 views ▪ Lisdexamphetamine for the treatment of methamphetamine withdrawal: Safety and feasibility - the OLAM study - 13,144 views ▪ Strengthening first line telephone support for people who use



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	consumers and busy healthcare professionals.		recipient) – 24th April 2023 <ul style="list-style-type: none"> ▪ The health & social characteristics of people who use methamphetamine in New South Wales (grant recipient) – 26th June 2023 ▪ Supporting healing on Nauo and Barngarla Country (Scholarship recipient) – 23rd October 2023 ▪ Exploring barriers to treatment-seeking with women who use methamphetamine – 8th March 2024 			Methamphetamine - 181 views <ul style="list-style-type: none"> ▪ The role of technology in therapy for methamphetamine use disorder (Fellowship recipient) – 208 views ▪ The health & social characteristics of people who use methamphetamine in New South Wales (seed funding recipient) - 218 views ▪ Supporting healing on Nauo and Barngarla Country (Scholarship recipient) - 202 views ▪ Exploring barriers to treatment-seeking with women who use methamphetamine – 288 views
<p>Testimonial in response to The GHB Cultures, Practices and Experiences study VAN: <i>“Absolutely brilliant, simple, clear, slick and impactful and very informative. Loved it, and so excited for the impact it will have. WAAC are fully supportive of endorsing and promoting it.” (CEO WAAC)</i></p> <p>Impact of the NSW Clinical Guidelines for withdrawal from alcohol and other drugs: These clinical guidelines had not been updated since 2008 and provide an imperative resource for clinicians working within the AOD sector.</p>						



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
3.b. Provide support for health professionals in the form of training, education and information resources clinical supervision, support and mentoring (which may be remote) opportunities	<p>NCCRED aimed to develop a webinar series in partnership with a clinical site to deliver content by experts in the field of AOD from across NSW and with the aim to showcase innovation and emerging research in the field to ensure AOD services across the state are informed of the latest evidence and practice.</p> <p>Following the pandemic, AOD clinicians are spending more time delivering care via non-traditional methods such as by telephone or online. This shift has resulted in unexpected benefits, such as increased capacity and reach in more regional and remote areas; however, delivery of telephone counselling presents a new challenge for some</p>	<p>Develop and provide Clinical research training in the form of webinars, training sessions and workshops to build clinical research capacity for clinicians in the AOD sector.</p> <p>Develop educational tools and resources in collaboration with partners to support health professionals working with AOD sector and improve outcomes for people who use drugs.</p>	<p>The Drug and Alcohol Research and Innovation Active-Learning network (DARIA) was held weekly between April 2022 and November 2023. DARIA sessions were recorded and available on the NCCRED website and NCCRED YouTube Channel.</p> <p>The AOD Telephone Counselling Toolkit was developed for counsellors transitioning to telephone-based care and those working in the ADIS', in partnership with Insight: Centre for Alcohol and other Drug Training and Workforce Development, and ADIS 24/7 Drug Support (QLD). Consisting of 2 modules "1: Foundational Concepts and Skills"; "2: Managing complex Calls", the modules include video and</p>		This activity was achieved.	<p>This activity was evaluated by attendance at webinar education sessions and engagement with the AOD Telephone Counselling Toolkit, developed from the training needs analysis conducted with five interstate ADIS's (see activity 3.c.)</p> <p>As of 30 June 2024, the DARIA series has had 48,575 views. For online attendees for each DARIA session as well as online views for each DARIA webinar please see Appendix 4.</p> <p>As of 30 June 2024, 897 participants have enrolled in Module 1 and 580 in Module 2. There were enrolments across all states and territories, and from the AOD sector, Mental health, Corrections/Justice health, General Practice, and Indigenous health among</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	professionals. Using the results of the training needs analysis developed with the ADIS's (see activity 3.c.), NCCRED, in collaboration with Insight: Centre for alcohol and other drug training and workforce development, set out to develop a new AOD telephone counselling toolkit. This toolkit would aim to contain eLearning modules, videos, tips and worksheets and other resources, leveraging off the expertise of telephone counsellors from ADIS 24/7 Alcohol and Drug Support. It would be the only comprehensive and free-to-access AOD telephone counselling resource in Australia.		<p>audio content, and were distributed across the AOD and Primary care sector on March 7th 2022. The AOD Telephone Counselling Toolkit can be found on the NCCRED website.</p> <p>After consultation with NGO peaks, NCCRED developed a series of webinars to with the aim to build evidence-based treatments, practices and outcomes for clients through clinical research called 'An introduction to evidence-based practice, clinical research and Good Clinical Practice (GCP) for clinicians working in the AOD sector'.</p> <ul style="list-style-type: none"> Webinar 1: Introduction to Evidence-Based Practice for clinicians in the AOD sector – Tuesday 2nd February 2021 			<p>others. 41% of learners worked for NGOs. In post-module evaluation, learners rated their overall satisfaction with the modules 90%.</p> <p>For online attendance for each of the webinars from the Evidence-based practice, clinical research and Good Clinical Practice (GCP) for clinicians working in the AOD sector series please see Appendix 4.</p> <p>In the reporting period 87 clinicians and academics received ICH-GCP training by NCCRED team members. This results in more AOD workers involved in research and trials have a greater understanding of all aspects of Good Clinical Practice and how it applies to everyday trial management. Which should result in better outcomes for clinical trials</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
			<ul style="list-style-type: none"> Webinar 2: Introduction to Clinical Research for clinicians in the AOD sector – Tuesday 9th February 2021 Webinar 3: Introduction to Good Clinical Practice in Clinical Research (ICH-GCP E6 R(2)) for clinicians working in the AOD sector – Tuesday 16th February 2021 <p>NCCRED held 8 International Conference on Harmonisation for Good Clinical Practice (ICH-GCP E6) transcelerate-accredited training workshops for the AOD sector.</p>			and their results for clients. For a full list of ICH-GCP workshops please see Appendix 4.
3.c. Develop and implement a quality improvement model in	Prior to this contract, NCCRED had identified that supporting the ADIS telephone advice services was a priority for the development and implementation of a quality	A training needs analysis for the ADIS for calls relating to methamphetamine and emerging drugs was conducted with five interstate ADIS's (NSW,	Data collection and analysis was compiled, and a Quality Improvement Model manuscript published in Drug and Alcohol Review in November 2023.		This activity was achieved.	This activity was evaluated by the responses from survey participants and the translation of its results into a training resource which can be used by clinicians within the AOD sector.



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
consultation with existing services	<p>improvement model, or training needs analysis.</p> <p>Fielding greater than 100,000 calls annually, telephone helplines are an important point of entry to alcohol and other drug (AOD) support in Australia as they are often the first point of contact for those who use methamphetamine and their family's seeking information, advice and referral. Notably, methamphetamine and emerging drugs can present a particular challenge for this workforce.</p> <p>Thus, NCCRED sought to identify training needs for these services, so that appropriate targeted resources can be developed. NCCRED established a partnership with the national ADIS</p>	<p>QLD, SA, Vic, WA) who serve all eight states and territories.</p> <p>The training needs analysis</p> <p>Published outputs with the results of the training needs analysis.</p>	<p>Results from the Training needs analysis was developed into the AOD Telephone Counselling Toolkit developed in partnership with Insight: Centre for Alcohol and other Drug Training and Workforce Development, and ADIS 24/7 Drug Support (QLD) (see activity 3.b.).</p>			<p>The training needs analysis had participants from all eight states and territories with a total of 50 participants. Of the 50, 29 participants completed the full survey. The results identified a need for: practical community-informed population relevant information for culturally and linguistically diverse populations and Aboriginal and Torres Strait Islander peoples for calls relating to methamphetamine and emerging drugs of concern; training and resources with a particular focus on families and friends of people who use methamphetamine and emerging drugs; and readily accessible up-to-date information on new and emerging drugs and treatment of related disorders.</p>



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	coordinating committee to review opportunities for sharing of knowledge and resources, as well as additional research, training and support needs and resource requirements to strengthen national first line response to individuals and families.					While a greater than 50% completion rate is acceptable, a higher completion rate would have been preferred. That being said, the results of the survey, identified important training themes which were able to be developed into the AOD Telephone Counselling Toolkit (see activity 3.b.)
3.d. Establish an information website and produce regular communications	<p>Prior to the current contract, NCCRED was required to establish an information website and produce regular webinars in order to translate evidence-based research outcomes into clinical practice and clinical guidelines and guidance products.</p> <p>The NCCRED website was launched in 2018 and was regularly updated with NCCRED research outputs, funding programs, translational outputs and</p>	The NCCRED website was continually updated with research outputs, symposia, webinars and other communications.	<p>52 newsletters were sent to NCCRED subscribers.</p> <p>An archive of all previously sent newsletters can be found on the NCCRED website.</p>		This activity was achieved.	<p>This activity was evaluated by audience numbers and engagement with communication outputs through newsletter registrations and social media engagement.</p> <p>Towards the end of the reporting period, NCCRED implemented new communication principles such as A/B testing to continuously improve communications. The total communications audience (email & social media)</p>



Australian Government

Community Grants Hub

Improving your grant experience



Objective		Outcomes				Evaluation
Activity	Background	Task(s)	Deliverable(s)	Status	Rationale for Status	Evaluation
	other communicate. This work has continued into this reporting period.					<p>increased by 10% between January 2024 to end June 2024.</p> <p>Additionally, the average open rate for email communications increased from 25% (Jul-Dec 2023) to 38% (Jan-Jun 2024), and our total number of unique email opens increased from 1654 to 3032 across the same period.</p>

Final Report Submission

Declaration:

- Grantee certifies that the above Final Report is not misleading by reason of any material misstatements or omissions.
- Grantee acknowledges that a change to the Activity without prior approval of the Commonwealth will be regarded as a breach of the Agreement, and the grant may consequently be reduced or revoked.
- Grantee acknowledges that under section 137.1 of the schedule to the *Criminal Code Act 1995* it is an offence to provide false or misleading information to the Commonwealth.
- The report must be signed by the Board, the Chief Executive Officer or an Authorised Officer of the Grantee.

<Legal Organisation Name>


Office Use only

Signed for and on behalf of:
University of New South Wales

Choose an item.
Include supporting comments where applicable

Name/Position:
Angela Wu, Grants Manager, Research Grants and Contracts

Assessed by:

Date: 03/ / 09 / 2024 

Date: / /

Additional signatory (where applicable)

Signed for and on behalf of:

Name/Position:

Date: / /

Appendices

Final Report

1 July 2020 – 30 June 2024

Appendix 1. Prompt Response Network membership



Appendix 2. Running Register of Clinical Research

Current NCCRED Led/Supported Research					
Chief Investigator	Organisation	Co-Investigators	Funding	Project Name	Further Information
Dr Krista J Siefried	NCCRED, UNSW, SVHS	A/Prof Adam Bourne, La Trobe A/Prof Garrett Prestage, The Kirby Institute, UNSW Dr Amy Peacock, NDARC, UNSW, UTAS Prof Kane Race, USYD Dr Jonathan Brett, SVHS Dr Mohamed Hammoud, The Kirby Institute, UNSW A/Prof Darren Roberts, RPAH Mr Joel Murray, ACON Mr Jack Freestone , UNSW, AIDS Council of NSW Mr Anthony Nedanoski, NA Mr Keaton Buhagiar, NDARC, St Vincent's Clinical School Ms Alanah Spillane, NCCRED, UNSW Ms Stephanie Riches-Evans , NCCRED, UNSW	NCCRED	A qualitative study exploring diverse cultures, practices and experiences of GHB use among people who identify as heterosexual and cisgender or transgender and live in Australia A quantitative study exploring diverse cultures, practices and experiences of GHB users in Australia: an anonymous cross-sectional survey.	VAN available on NCCRED website
A/Prof Garret Prestage	Kirby Institute, UNSW	Prof Nadine Ezard , SVHS, NCCRED Prof Louisa Degenhardt, NDARC, UNSW Prof Lisa Maher, Kirby Institute, UNSW A/Prof Anna McNulty, Sydney Sexual Health Dr Dean Murphy, The Kirby Institute, UNSW Dr Krista J Siefried , NCCRED, UNSW, SVHS	NHMRC	Implementing population-specific psychosocial interventions to optimise treatment, care and support among men who have sex with men who use methamphetamine	
Dr Jonathan Brett	SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Dr Angela Chiew, Prince of Wales Hospital Dr Nazila Jamshidi, RPAH Mr Liam Acheson , SVHS, NCCRED, NDARC, UNSW	Unfunded	Gamma-hydroxybutyrate Overdose in Inner-Sydney Emergency Departments: a retrospective review (the GO Study)	
Dr Jonathan Brett	SVHS	Dr Krista Siefried , NCCRED, UNSW, SVHS Prof Joga Chaganti, SVHS Prof Bruce Brew, SVHS Mr Liam Acheson , SVHS, NCCRED, NDARC, UNSW	SVHS Clinic Foundation	Neural correlates of methamphetamine use disorder	

Completed NCCRED Led/Supported Research

Chief Investigator	Organisation	Co-Investigators	Funding	Project Name	Further Information
Dr Krista J Siefried	NCCRED, UNSW, SVHS	Prof Nadine Ezard , SVHS, NCCRED Dr Michael Christmass, Next Step, WA Prof Paul Haber, RPAH-DHS, USYD Prof Robert Ali, Adelaide University	NCCRED	A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia	Publication
Prof Nadine Ezard	NCCRED, UNSW, SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Mr Brendan Clifford , USYD, SVHS Prof Adrian Dunlop, HNELHD, D&A Clinical Services A/Prof Raimondo Bruno, UTAS Prof Andrew Carr, SVHS Dr Zhixin Liu, Stats Central, UNSW Prof Nicholas Lintzeris, SESLHD, D&A Services	NSW MoH	Dose-escalating, phase 2 safety study of oral lisdexamfetamine in adults with methamphetamine dependence	Publication
Dr Jonathan Brett	SVHS	Ms Amy Healey, UNSW Dr Krista J Siefried , NCCRED, UNSW, SVHS Ms Mary Ellen Harrod, DanceWize NSW, NUA Ms Erica Franklin, DanceWize NSW, NUA Dr Amy Peacock, NDARC, UNSW, UTAS Dr Monica J. Barratt, RMIT University	Unfunded	Correlates of higher risk drug related behaviours at music festivals in New South Wales, Australia	Publication
Dr Jonathan Brett	SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Ms Amy Healey, UNSW Ms Mary Ellen Harrod, DanceWize NSW, NUA Ms Erica Franklin, DanceWize NSW, NUA Dr Monica J. Barratt, Research/Policy, RMIT University Mr Gem Masters, USYD Ms Lynn Nguye, USYD Mr Santosh Adiraju, Uni SA Mr Cobus Gerber, Uni SA	Unfunded	Wastewater analysis for psychoactive substances at music festivals across New South Wales, Australia in 2019-2020	Publication
Prof Nadine Ezard	SVHS, NCCRED	Mr Liam Acheson , SVHS, UNSW, NCCRED Dr Krista J Siefried , NCCRED, UNSW, SVHS Mr Brendan Clifford , USYD, SVHS Ms Emily Murray, SVHS Ms Maureen Steele, SVHS Dr Liesa Clagues, USYD, Ms Victoria Malone, NSW MoH A/Prof Darren Roberts, RPAH Ms Lisa-Jayne Ferguson, SVHS Prof Gail V Matthews, Kirby Institute, UNSW, SVHS	SVHA Inclusive Health	One third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: A retrospective medical record review	Publication

Dr Krista J Siefried	NCCRED, UNSW, SVHS	Mr Liam Acheson , SVHS, NCCRED, NDARC, UNSW Dr Benjamin Williams, RPAH Prof Michael Farrell, NDARC, UNSW Dr Rebecca McKetin, NDARC, UNSW Prof Nadine Ezard , NCCRED, UNSW, SVHS	NCCRED	Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials	Prospero Registration Publication VAN available on NCCRED website ANZCTR Listing
Dr Krista J Siefried	NCCRED, UNSW, SVHS	Prof Nadine Ezard , SVHS, NCCRED, UNSW Prof Adrian Dunlop, HNELHD, D&A Clinical Services Prof Nicholas Lintzeris, SESLHD, D&A Services Dr Jonathan Brett, SVHS, D&A Service, Clinical Pharmacology and Toxicology Mr Liam Acheson , SVHS, UNSW, NCCRED Dr Craig Rodgers, SVHS, D&A Service Prof Anthony Gill, SVHS, D&A Service Prof Michael Farrell, NDARC, UNSW A/Prof Rebecca McKetin, NDARC, UNSW, Dr Michael Christmass, Next Step, Western Australia Prof Steve Shoptaw, UCLA	NCCRED	An open-label trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal (the OLAM study)	Publication VAN available on NCCRED website
Dr Krista J Siefried	NCCRED, UNSW, SVHS	A/Prof Adam Bourne, La Trobe A/Prof Garrett Prestage, The Kirby Institute, UNSW Dr Amy Peacock, NDARC, UNSW, UTAS Prof Kane Race, USYD Dr Jonathan Brett, SVHS, D&A Service, Clinical Dr Mohamed Hammoud, The Kirby Institute, UNSW A/Prof Darren Roberts, RPAH Mr Joel Murray, ACON	NCCRED	A qualitative study exploring diverse cultures, practices and experiences of GHB use among LGBTQ Australians	Study Website VAN available on NCCRED website
Prof Nadine Ezard	NCCRED, UNSW, SVHS	Ms Florence Bascombe , NCCRED, UNSW, SVHS Mr Peter Middleton, SVHS Dr Krista J Siefried , NCCRED, UNSW, SVHS Mr Brendan Clifford , USYD, SVHS Prof Frances Kay-Lambkin, University of Newcastle Ms Jessica Wilson, University of Newcastle Dr Zhixin Liu, Stats Central, UNSW	NSW MoH	Feasibility and efficacy of the S-Check App: A harm reduction and early intervention smartphone application for methamphetamine use	Study Website
Prof Nadine Ezard	NCCRED, UNSW, SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Ms Victoria Malone, NSW MoH Dr Kathryn Van Gordon, General Practice Mr Brendan Clifford , USYD, SVHS Mr Duncan Graham , NCCRED Dr Fiona Magee, General Practice	Unfunded	Barriers to stimulant treatment access for women who use methamphetamine in inner Sydney: a qualitative study	VAN available on NCCRED website

Prof Nadine Ezard	NCCRED, UNSW, St Vincent's Hospital Sydney (SVHS)	Prof Adrian Dunlop, HNELHD, Drug & Alcohol (D&A) Clinical Services Dr Willy Liaw, South Australia (SA) Health A/Prof Mike McDonough, SA Health Prof Robert Ali, Adelaide University Prof Jason White, Uni SA A/Prof Rebecca McKetin, NDARC, UNSW A/Prof Raimondo Bruno, University of Tasmania (UTAS) Prof Andrew Carr, SVHS Dr Craig Rodgers, SVHS, D&A Service Prof Anthony Gill, SVHS, D&A Service Dr Mark Montebello Northern Sydney LHD (NSLHD) Prof Michael Farrell, NDARC, UNSW Prof Paul Haber, RPAH-DHS, University of Sydney Prof Dan Lubman, Turning Point, Monash University, Eastern Health Clinical School (EHCL) Dr Robert Graham, Western Sydney LHD (WSLHD) Dr Keith Heinzerling, University of California, Los Angeles (UCLA) Prof Nicholas Lintzeris, SESLHD, D&A Services Dr Krista J Siefried , NCCRED, UNSW, SVHS	NHMRC	A randomised double-blind placebo-controlled study of lisdexamfetamine for the treatment of methamphetamine dependence (LiMA Study)	ANZCTR Listing
Prof Nadine Ezard	NCCRED, UNSW, SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Beatrice Webb, UTAS Mr Brendan Clifford , USYD, SVHSx Mr Michael E Cecilio NSW MoH, Ms Amanda Jellie, School of Medicine, Sydney, Notre Dame Dr Toby Lea, Centre for Social Research in Health, UNSW Dr Craig Rodgers, SVHS, D&A Service Mr Simon Ruth, Thorne Harbour Health A/Prof Raimondo Bruno, UTAS	St Vincent's Health Australia (SVHA) Inclusive Health	The Substance Use and Sex Index (SUSI) study	Study Website
Dr Jonathan Brett	SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Dr Elizabeth Knock, NCCRED Scholar, SVHS Mr Steven Albert, SVHS Dr Paul Likhaitzky, Monash University Dr Margaret Ross, SVHM Prof Richard Day, SVHS Prof Nadine Ezard , SVHS, NCCRED Dr Joga Chaganti, SVHS	NCCRED Scholarship	Psilocybin-facilitated treatment for methamphetamine Use Disorder: A pilot study (Psi-MA)	
Ms Florence Bascombe	NCCRED, UNSW, SVHS	Dr Krista J Siefried , NCCRED, UNSW, SVHS Ms Stacey Child, Mental Health Commission WA Ms Lynn Stevens, DASSA	Unfunded	A Training needs analysis for the ADIS for calls relating to Methamphetamine and Emerging Drugs (ADIS MED TNA)	VAN available on NCCRED website

		Dr Hollie Wilson ADIS 24/7, QLD Health Mr Rick Loos, Turning Point, VIC Prof Nadine Ezard , NCCRED, UNSW, SVHS			
Cassandra Wright	Menzies School of Health Research (MSHR), Northern Territory	Mia Miller, The George Institute for Global Health Tessa Wallace, MSHR Sarah Clifford, MSHR Peter Burnheim, AADANT Dr Penelope Hill, NCCRED UNSW A/Prof Megan Lim, Burnett Institute Prof Paul Dietze, Burnett Institute	Menzies School of Health Research	Baseline in the Grass: Investigating alcohol and drug use among festival attendees,	Publication
Dr Krista Siefried	NCCRED, UNSW, SVHS	Prof Nadine Ezard – NCCRED, UNSW, SVHS A/Prof Adam Bourne – La Trobe University A/Prof Garrett Prestage – UNSW, Kirby Institute Dr Amy Peacock – UNSW, NDARC Prof Kane Race – University of Sydney Dr Jonathan Brett – SVHS, Alcohol and drug services Dr Mohamed Hammoud – UNSW, Kirby Institute A/Prof Darren Roberts – SVHS, Alcohol and drug services Mx. Joel Murray - ACON	NCCRED	A qualitative study exploring diverse cultures, practices and experiences of GHB use among heterosexual, cisgender and transgender Australians	
Dr Krista Siefried	NCCRED, UNSW, SVHS	Prof Nadine Ezard – NCCRED, UNSW, SVHS A/Prof Adam Bourne – La Trobe University A/Prof Garrett Prestage – UNSW, Kirby Institute Dr Amy Peacock – UNSW, NDARC Prof Kane Race – University of Sydney Dr Jonathan Brett – SVHS, Alcohol and drug services Dr Mohamed Hammoud – UNSW, Kirby Institute A/Prof Darren Roberts – SVHS, Alcohol and drug services Mx. Joel Murray – ACON Dr Jack Freestone – NCCRED, UNSW, ACON Mr Anthony Nedanoski – consumer Mr Nic Robinson-Griffith – Thorne Harbour Health Ms Kristina Mitsikas – Western Australian AIDS Council Mr Christopher Theodoridis - ACON	NCCRED	A quantitative study exploring diverse cultures, practices and experiences of GHB users in Australia: an anonymous cross-sectional online survey	
Dr Krista Siefried	NCCRED, UNSW, SVHS	Ms Penny Hill – NCCRED Ms Stephanie Riches-Evans – NCCRED	NCCRED	Prompt Response Network Australian Clinical Research Priority Setting Study	

Completed NCCRED Funded Research					
Chief Investigator	Organisation	Co-Investigators	Funding	Project Name	Further Information
Prof Paul Haber	SLHD	A/Prof Kirsten Morley, USYD, RPAH-DHS Dr Chris Tremonti, SLHD, RPAH-DHS Ms Elaine Doherty, SLHD, RPAH-DHS Mr Amos He, SLHD, RPAH-DHS Ms Zara Mills, SLHD, RPAH-DHS Mr Joel Hillman, SLHD RPAH-DHS	NCCRED Capacity Building	The LiMA@RPAH study: a randomised double-blind placebo-controlled study of lisdexamfetamine for the treatment of methamphetamine dependence	NCCRED website Final report received
Prof Nicholas Lintzeris	SESLHD	Dr Rachel Deacon, Division Addiction Medicine, USYD Prof Anthony Shakeshaft, NDARC, UNSW Dr Michelle Cretikos, Centre Population Health, NSW MoH Ms Jeniffer Holmes, NSW MoH, Drug and Alcohol Nurses Australasia Ms Kristie Mammen, D&A Services, SESLHD Prof Nadine Ezard, SVHS, NCCRED Dr Llewellyn Mills, USYD, D&A Services, SESLHD Prof Michael Farrell, NDARC, UNSW Prof Adrian Dunlop, HNELHD, D&A Clinical Services Dr Krista J Siefried, NCCRED, UNSW, SVHS	NCCRED Capacity Building	Developing a clinical data laboratory for methamphetamine use in NSW: The MAData project	Publication Publication Publication NCCRED website Final report received
Dr Peter Stockham	Forensic Science SA	Dr Sam Alfred, Royal Adelaide Hospital Dr Daniel Haustead, Royal Adelaide Hospital, The Queen Elizabeth Hospital Dr Emma Partridge, Forensic Science SA Mr Chris Kostakis, Forensic Science SA Prof Jason White, The University of South Australia Prof Andrew Camilleri, The University of South Australia	NCCRED Capacity Building	South Australian Drug Early Warning System – Emergency Department Admission Blood Psychoactive Testing (EDAPT)	Publication Publication Publication NCCRED website Final report received
Briony Larance	University of Wollongong	A/Prof Peter Kelly, UOW Dr Luise Lago, UOW Dr Julia Lappin, NDARC, UNSW School of Psychiatry Dr Laura Robinson, UOW, School of Psychology Ms Sarah Adams, Illawarra Shoalhaven LHD (ISLHD), Illawarra D&A Services Mr David Reid, ISLHD, Illawarra D&A Services	NCCRED Seed Round 1	Increasing the capacity of a local health district to respond to methamphetamine-related harm: developing an integrated model of care informed by linked data and consumer and clinician views	NCCRED website Final report received
Dr Jessamine Soderstrom	Royal Perth Hospital	Dr David McCutcheon, Royal Perth Hospital Dr Julia George, Royal Perth Hospital Dr Mohan Raghavan, Royal Perth Hospital	NCCRED Seed Round 1	Emerging Drug Network of Australia (EDNA)	Publication Publication

		Mr Jonathon Burcham, Royal Perth Hospital Professor Daniel Fatovich, Royal Perth Hospital Mr Francois Oosthuizen, ChemCentre WA Dr Shaun Greene, Austin Hospital, Victoria Prof Andrew Dawson, RPAH, NSW Dr Kylie McArdle, NSW PIC Mr Jared Brown, NSW PIC Dr Katherine Isoardi, Princess Alexandra Hospital, QLD Dr Sam Alfred, Royal Adelaide Hospital, SA Dr Edward Archer, Royal Darwin Hospital Mr Paul Dessauer, Harm Reduction WA			NCCRED website Final report received
Dr Gill Bedi	The University of Melbourne	Mr Alexandre Arthur Guerin, University of Melbourne Dr Eddie Mullen, Orygen Dr Enrico Cementon, Orygen Dr Paul Amminger, University of Melbourne, Orygen Dr Andrew Chanen, University of Melbourne, Orygen Dr Shalini Arunogiri, Turning Point, Monash University,	NCCRED Seed Round 2	An open-label pilot study of sub-anaesthetic ketamine for methamphetamine abuse in young people	ANZCTR Listing NCCRED website Final report received
A/Prof Peter Kelly	UOW	Dr Allison Beck, UOW Dr Briony Laranca, UOW Prof Amanda Baker, University of Newcastle Prof Frank Deane, UOW Prof Leanne Hides, University of QLD A/Prof Victoria Manning, Monash University, EHCL Prof Anthony Shakeshaft, NDARC, UNSW Dr Angela Argent, Smart Recovery Australia	NCCRED Seed Round 2	Methamphetamine and mutual support: a mixed methods exploration of SMART Recovery participants' characteristics and opportunities for enhanced referral pathways	Publication Publication NCCRED website Final report received
A/Prof Victoria Manning	Monash University	Dr Joshua B.B Garfield, Monash University, EHCL Dr Shalini Arunogiri, Monash University, EHCL Prof Daniel Lubman, Monash University, EHCL Mr Jeffery Gavin, APSU Dr Goke Okedara, Albert Road Clinic Prof Malcolm Hopwood, University of Melbourne, Albert Road Clinic	NCCRED Seed Round 2	A pilot randomised controlled trial (RCT) of personalised approach bias modification for methamphetamine use disorder	ANZCTR Listing Publication NCCRED website Final report received
A/Prof James Ward	South Australian Health and Medical Research Institute (SAHMRI)	Dr Rachel Reilly, SAHMRI, University of Adelaide, Flinders University A/Prof Rebecca McKetin, NDARC, UNSW Prof Nadine Ezard, SVHS, NCCRED Scientia Prof Carla Treloar, UNSW Prof Adrian Dunlop, HNELHD, University of Newcastle A/Prof Handan Wand, Kirby Institute, UNSW A/Prof Yvette Roe, Charles Darwin University, Mater Medical Research Institute Limited, University of QLD Dr Julia Butt, NDRI, Curtin University Dr Brendan Quinn, Australian Institute of Family Studies	NCCRED Seed Round 2	An acceptability and feasibility study of the We Can Do This online therapeutic program in primary care and residential rehabilitation settings	NCCRED website Final report received

Dr Shalini Arunogiri	Turning Point, Monash University, EHCL	A/Prof Victoria Manning, Monash University, EHCL Dr Gill Bedi, University of Melbourne; Orygen Dr Adam Rubenis, Turning Point A/Prof Rebecca McKetin, NDARC, UNSW A/Prof Femke Buisman-Pijlman, University of Melbourne Prof Iain S. McGregor, USYD, Prof Daniel Lubman, EHCL, Monash University	NCCRED Seed Round 3	An open label pilot study of intranasal oxytocin for methamphetamine withdrawal in women	NCCRED website Final report received
Dr Monica Barratt	RMIT University	A/Prof Alan Eade, Clinical Safe Care Vic, Monash Uni Ms Catherine Quinn, Forensic Victoria Police Ms Joanne Gerstner-Stevens, Forensic Victoria Police Mr Tom Lyons, Victorian Department of Health Prof Nicole Lee, 360Edge, NDRI, Curtin University Mr Sione Crawford, Harm Reduction Victoria Ms Stephanie Tzanetis, Harm Reduction Victoria Ms Virginia McKinnon, Uniting ReGen Ms Rita Brien, Turning Point, EHCL, Monash University Ms Isabelle Volpe, Turning Point, EHCL, Monash University Dr Jasmin Grigg, Monash University, Turning Point, A/Prof Caitlin Hughes, Centre for Crime Policy and Research, Flinders University	NCCRED Seed Round 3	Rapid translation of forensic data from police drug seizures into clinical alerts to improve public health	Publication Publication NCCRED website Final report received
A/Prof Peter Kelly	UOW	Dr Briony Larence, UOW Prof Amanda Baker, University of Newcastle A/Prof Victoria Manning, Monash University, EHCL Dr Angela Argent, Smart Recovery Australia Dr Allison Beck, UOW A/Prof Brian Hitsman, Northwestern university, USA Prof Frank Deane, UOW Prof Leanne Hides, University of Queensland Prof Anthony Shakeshaft, NDARC, UNSW Prof Richard Velleman, Bath University	NCCRED Seed Round 3	BeSMART: feasibility and preliminary efficacy of an intervention for family members impacted by methamphetamine	Publication NCCRED website Final report received
A/Prof Suzanne Nielsen	Monash University	Ms Sarah Hiley, MSIR North Richmond Community Ms Julie Latimer, Uniting MSIC Dr Nico Clark, North Richmond Community Health, Melbourne University, Royal Melbourne Hospital Dr Marianne Jauncey, Uniting MSIC, NDARC UNSW Dr Monica Barratt, Social and Global Studies Centre, RMIT University Dr Emma Tay, WSLHD A/Prof Dimitri Gerostamoulos, Victorian Institute of Forensic Medicine (VIFM), Monash University Ms Linda Glowacki, VIFM Prof Claude Roux, UTS, Centre for Forensic Science Dr Marie Morelato, UTS Centre for Forensic	NCCRED Seed Round 3	Understanding emerging opioid-related harms through improved surveillance, drug checking and information sharing systems	Publication Publication NCCRED website Final report received

		Ms Elodie Lefrancois, University of Lausanne, Switzerland, UTS Centre for Forensic Science Ms Tina Lam, Monash University, NDRI, Curtin University Mr Michael Gilbert, Independent consultant			
Prof Antonio Verdejo-Garcia	Monash University	Mr Eric Allan, Odyssey House Victoria Prof Daniel Lubman, EHCL, Monash University	NCCRED Seed Round 3	Determining the feasibility and efficacy of Goal Management Training for improving treatment retention and outcomes during residential treatment for methamphetamine dependence	ANZCTR Listing Publication Publication Publication Publication NCCRED website Final report received
Dr Amy Peacock	NDARC, UNSW, UTAS	Dr Rachel Sutherland, NDARC, UNSW A/Prof Raimundo Bruno, UTAS Dr Monica Barratt, NDARC, UNSW, Social and Global Studies Centre, RMIT University Dr Mary Harrod, NSW Users and AIDS Association (NUAA), UNSW Mr Gulliver McLean, NUAA Prof Harry Sumnall, Public Health Institute, Liverpool John Moores University Mr Robin Auld, Centre for Population Health, NSW Ministry of Health (MoH) Mr Jared Brown, Centre for Population Health, NSW MoH Dr Robert Page, The Loop Australia / SVHS Ms Penny Hill, NCCRED, UNSW A/Prof Nadine Ezard, NCCRED, UNSW, SVHS Ms Greta Baillie, NDARC, UNSW	NCCRED Seed Round 3	Risk communication for people who use MDMA/‘ecstasy’ and related drugs: establishing guidance on consumer preferences and behavioural responses to drug alerts	Publication NCCRED website Final report received
Dr Gill Bedi	University of Melbourne	Mr Alexandre Arthur Guerin, University of Melbourne Dr Eddie Mullen, Orygen Dr Enrico Cementon, Orygen Dr Paul Amminger, University of Melbourne, Orygen Dr Andrew Chanen, University of Melbourne, Orygen Dr Shalini Arunogiri, Monash University; EHCL	NCCRED Seed Round 4	Cannabidiol – A novel pharmacotherapy for Lowering Methamphetamine use (The CALM Study)	Publication NCCRED website Final report received
A/Prof Peter Kelly	UOW	Dr Jamie Berry, Advanced Neuropsychological Treatment Services, Macquarie University Ms Sarah Adams, D&A Service, ISLHD A/Prof Vida Bliokas, UOW, Illawarra Health and Medical	NCCRED Seed Round 4	Feasibility and preliminary efficacy of Cognitive Remediation Groups in a community outpatient setting for people who use methamphetamines.	NCCRED website Final report received

		Research Institute (IHMRI) Dr Siyu Qian, D&A Service, ISLHD Ms Joanne Lunn, UOW, School of Psychology			
Dr Buddhima Lokuge & Dr. Tarun Yadav	HNELHD	Dr Tarun Yadav, D&A Clinical Services, HNELHD Dr Marcia Sequeira, D&A Clinical Services, HNELHD Mr Martin Nean, D&A Clinical Services, HNELHD Dr Amanda Brown, D&A Clinical Services, HNELHD Dr Llewellyn Mills, USYD, D&A Services, SESLHD Dr Bryan Paton, University of Newcastle; IHMRI Prof Adrian Dunlop, HNELHD, D&A Clinical Services	NCCRED Seed Round 4	Theta burst Transcranial Magnetic Stimulation (TMS) for Methamphetamine use disorder– A feasibility study to inform the design of a multisite randomised control trial.	Publication NCCRED website Final report received
A/Prof Rebecca Mcketin	NDARC, UNSW	Dr Shalini Arunogiri, Monash University Dr Alison Marshall, Kirby Institute, UNSW Dr Simon Clay, UNSW Miss Samantha College, NDARC, UNSW A/Prof Meredith Ginley, Eastern Tennessee State Uni Mr Jack Nagle, Connections Based Living Dr Michael Christmass, Next Step, WA Dr Paul McCartney, Co-health Dr Dean Membrey, Cohealth Prof Michael Farrell, NDARC, UNSW Prof Louisa Degenhardt, NDARC, UNSW Prof Jason Grebely, Kirby Institute, UNSW	NCCRED Seed Round 4	Integrating contingency management for methamphetamine use into routine clinical care in Australia	Publication Publication NCCRED website Final report received
Dr Llewelyn Mills	SESLHD	Prof Nicholas Lintzeris, SESLHD, D&A Services Prof Adrian Dunlop, HNELHD, D&A Clinical Services Prof Michael Farrell, NDARC, UNSW Dr Rachel Deacon, Division Addiction Medicine, USYD Prof Anthony Shakeshaft, NDARC, UNSW Ms Kristie Mammen, D&A Services, SESLHD Ms Jennifer Holmes, Centre for AOD, NSW MoH Dr Michelle Cretikos, Centre Population Health, MoH Dr Emma Black, D&A Services, SESLHD, USYD Mr Steven Childs, Central Coast LHD Dr David Reid, ISLHD Dr Mark Montebello, NSLHD Ms Sophie Maiolo, SESLHD D&A Services	NCCRED Seed Round 4	Examining the effects of Amphetamine-Type-Substance use on clinical outcomes among clients receiving opioid agonist treatment	NCCRED website Final report received
Dr Robert Page		Dr Marianne Jauncey, Uniting MSIC Prof Alison Ritter, UNSW Sydney Dr Monica Barratt, RMIT University Dr Richard Kevin, The Loop Australia A/Prof Suzanne Nielsen, Monash University Ms Sharon Neville, FASS Ms Una Cullinan, FASS Mr Jacob Fry, The Loop Australia	NCCRED Seed Round 4	Co-designing a fixed-site drug checking service at Sydney's Medically Supervised Injecting Centre (MSIC)	NCCRED website Final report received

		Mr Matt Dibbayawan, The Loop Australia Prof Ian McGregor, University of Sydney Mr Cameron Francis, The Loop Australia Dr Cheneal Puljevic, The Loop Australia Ms Sarah Hiley, The Loop Australia Prof Fiona Measham, University of Liverpool			
Dr Adam Rubenis	Turning Point, Eastern Health	Prof Amanda Baker, University of Newcastle Dr Shalini Arunogiri, Turning Point, Monash University Dr Elizabeth Katz, Towson University, Maryland, USA Dr Jennifer Nation, Turning Point (Eastern Health); Monash University	NCCRED Fellow	Researching Methamphetamine use and technology-mediated psychosocial interventions	Publication NCCRED website Final report received
Dr Edward Mullen	Orygen	Dr Gill Bedi, The University of Melbourne Mr Alexandre Arthur Guerin, University of Melbourne Dr Eddie Mullen, Orygen Dr Enrico Cementon, Orygen Dr Paul Amminger, University of Melbourne, Orygen Dr Andrew Chanen, University of Melbourne, Orygen Dr Shalini Arunogiri, Turning Point, Monash University, EHCL	NCCRED Fellow	The Methamphetamine use in young people: Sub-anaesthetic Ketamine Open-label Trial (MASKOT) protocol	ANZCTR Listing NCCRED website Final report received
Dr Andrew Kozman	Royal Perth Hospital	Dr Jessamine Soderstrom, Royal Perth Hospital Dr David McCutcheon, Royal Perth Hospital Dr Julia George, Royal Perth Hospital Dr Mohan Raghavan, Royal Perth Hospital Mr Jonathon Burcham, Royal Perth Hospital Professor Daniel Fatovich, Royal Perth Hospital Mr Francois Oosthuizen, ChemCentre WA Dr Shaun Greene, Austin Hospital, Victoria Prof Andrew Dawson, RPAH, NSW Dr Kylie McArdle, NSW PIC Mr Jared Brown, NSW PIC Dr Katherine Isoardi, Princess Alexandra Hospital, QLD Dr Sam Alfred, Royal Adelaide Hospital, SA Dr Edward Archer, Royal Darwin Hospital Mr Paul Dessauer, Harm Reduction WA	NCCRED Fellow	Emerging Drugs Network of Australia	Publication Publication NCCRED website Final report received
Dr James Gooden	Turning Point, Eastern Health	Dr Catherine A. Cox, Turning Point, Eastern Health Dr Vanessa Petersen, Turning Point, Eastern Health Ms Georgia L. Bolt, Turning Point, Eastern Health A/Prof Victoria Manning, Monash University, EHCL Prof Daniel Lubman, Turning Point, Monash University, EHCL Dr Shalini Arunogiri, Turning Point, Monash University, EHCL	NCCRED Scholar	Investigating the outcomes of providing neuropsychological assessment to individuals with alcohol or polysubstance use histories attending Alcohol and Other Drug treatment services.	Publication Publication NCCRED website Final report received

Dr Elizabeth Knock	SVHS	Dr Jonathan Brett, SVHS, D&A Service, Clinical Dr Krista J Siefried, NCCRED, UNSW, SVHS Dr Elizabeth Knock, NCCRED Scholar, SVHS Mr Steven Albert, SVHS Dr Paul Liknaitzky, Monash University Dr Margaret Ross, SVHM Prof Richard Day, SVHS Prof Nadine Ezard, SVHS, NCCRED Dr Joga Chaganti, SVHS	NCCRED Scholar	Psilocybin-facilitated treatment for methamphetamine Use Disorder: A pilot study (Psi-MA)	Publication NCCRED website Final report received
Mr Jason Ramp	West Coast Youth and Community Support	A/Prof James Ward, South Australian Health and Medical Research Institute (SAHMRI) Dr Rachel Reilly, SAHMRI, University of Adelaide, Flinders University A/Prof Rebecca McKetin, NDARC, UNSW Prof Nadine Ezard, SVHS, NCCRED Scientia Prof Carla Treloar, UNSW Prof Adrian Dunlop, HNELHD, University of Newcastle A/Prof Handan Wand, Kirby Institute, UNSW A/Prof Yvette Roe, Charles Darwin University, Mater Medical Research Institute Limited, University of QLD Dr Julia Butt, NDRI, Curtin University Dr Brendan Quinn, Australian Institute of Family Studies	NCCRED Scholar	Evaluating innovative AOD programs for Aboriginal and Torres Strait Islander people on Barnagarla and Nauo Country	NCCRED website Final report received

Appendix 3. Running Register of Clinical Guidelines and Best Practice Models

Title	Publication date	Authors	Dissemination
Clinical guide for the management of methamphetamine use disorder in primary care (online & print)	Updated June 2022	Bascombe, F; Ezard, N	NCCRED Website 290 print copies distributed to 29 clinicians/clinical sites
Naloxone – Consumer guidance note (online)	Updated June 2021	Hill, P; Bascombe, F; Ezard, N	NCCRED Website
A matrix of clinical research treatment outcomes for amphetamine/methamphetamine dependence	September 2020	Siefried, K; Acheson, L; Lintzeris, N; Ezard, N	NCCRED Website
A workforce development strategy for clinical researchers in emerging drugs to June 2022	July 2020	NCETA/NCCRED	Internal document, submitted to Department 2020
Australian methamphetamine-related clinical guidelines matrix – by treatment setting and population type	June 2020	Bascombe, F; Roche, A; Ryan, K; Fischer, J; Nicholas, R	NCCRED Website
Carfentanil – Consumer guidance note (online & print)	March 2020	Bascombe, F; Ezard, N	NCCRED Website
Fentanyl – Consumer guidance note (online & print)	March 2020	Bascombe, F; Ezard, N	NCCRED Website
St. Vincent’s S-Check clinic model of care	December 2019	Sullivan, F; Bascombe, F; Ezard, N	NCCRED Website
Management of withdrawal from alcohol and other drugs: an evidence check rapid review brokered by the Sax Institute for the Ministry of Health	September 2019	Lintzeris, N; Sunjic, S; Demirkol, A; Branezac, M; Ezard, N; Siefried, K; Acheson, L; Bascombe, F; Tremonti, C; Haber, P.	SAX Institute Website
A review of Australian clinical guidelines for methamphetamine use disorder	June 2019	Roche, A; Ryan, K; Fischer, J; Nicholas, R	NCCRED Website

Appendix 4. Running Register of Training and Education Sessions

Training & Education Sessions	Name & Date of Sessions	Attendees
Drug and Alcohol Research and Innovation Network (DARIA)	<ul style="list-style-type: none"> - Pharmacotherapy for Methamphetamine Use Disorder – 4th April 2022 - Methadone Buprenorphone Transfers – 11th April 2022 - Meds for Methamphetamine – 2nd May 2022 - The role of electronic cigarettes to quit smoking – 9th May 2022 - Psychedelics for the treatment of substance use disorders – 16th May 2022 - Pharmacotherapies for Methamphetamine Withdrawal – 23rd May 2022 - Nitrous Oxide induced myelo-neuropathy – 30th May - GHB Experiences and cultures of practices amongst LGBTQ people – 6th June 2022 - Capacity and Substance Use Disorder – Alcohol – 20th June 2022 - ChemSex and harm reduction for gay and bisexual men in Australia – 27th June 2022 - Telehealth Ambulatory Alcohol Withdrawal: Clean Slate Clinic – 4th July 2022 - Baclofen to prevent relapse in GHB dependent patients – 11th July 2022 - Motivational Interviewing and Trauma in the AOD space – 18th July 2022 - Methamphetamine use during pregnancy – 25th July 2022 - Alcohol use in Aboriginal and Torres Strait Islander Communities: Recent research and evidence – 1st August 2022 - Clinical management of cannabis withdrawal – 8th August 2022 - Use of dexmedetomidine in alcohol withdrawal delirium – 15th August 2022 - Injectable Hydromorphone – Feasibility of Opioid Injecting Trial (FOPiT) – 22nd August 2022 - Opioid Vs opioid-free analgesia after surgical discharge – 29th August 2022 - Open-label trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal (the OLAM study) – 5th September 2022 - Motivational Interviewing – 12th September 2022 - Novel Opioids – Case Series on the use of Kamini – 19th September 2022 - Alcohol and Drug Cognitive Enhancement (ACE) program – 26th September 2022 - Case Management and Care Planning Clinical Guidelines in the AOD sector – 17th October 2022 - Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder A Randomized Clinical Trial – 24th October 2022 - Performance & Image Enhancement: what should health services be doing? – 31st October 2022 - Situational Counselling for Domestic Violence Disclosure – AOD Context – 14th November 2022 - Cannabis hyperemesis management – 21st November 2022 	<ul style="list-style-type: none"> - 25 attended / 119 views online - 20 attended / 77 views online - 29 attended / 119 views online - 29 attended / 18 views online - 21 attended / 49 views online - 23 attended / 96 views online - 26 attended / 139 views online - 36 attended / 48 views online - 39 attended / 54 views online - 31 attended / 499 views online - 28 attended / 118 views online - 22 attended / 456 views online - 30 attended / 77 views online - 30 attended / 1,180 views online - 34 attended / 123 views online - 28 attended / 287 views online - 36 attended / 52 views online - 28 attended / 443 views online - 34 attended / 37 views online - 34 attended / 191 views online - 48 attended / 186 views online - 44 attended / 32,532 views online - 31 attended / 191 views online - 37 attended / 385 views online - 24 attended / 99 views online - 19 attended / 54 views online - 33 attended / 59 views online - 21 attended / 229 views online

	<ul style="list-style-type: none"> - Drug Testing in addiction medicine – 28th November 2022 - An Australian National Prompt Response Network for emerging drugs – 5th December 2022 - Poppy Seed tea and Thebaine Poisoning – 12th December 2022 - Strengthening first-line telehealth for people who use Methamphetamine and Emerging Drugs – 17 April 2023 - Discontinuation of Opioid Treatment Program – 15th May 2023 - Using health data to understand people who use Amphetamine – 19th June 2023 - Long term patterns of heroin use and mental health – 20 years on – 17th July 2023 - Psychosocial interventions for families affected by another’s alcohol or other drug use – 21st August 2023 - Sleep, circadian rhythms and substance use – 18th September 2023 - Responding to emerging drugs of concern: nitazenes – 25th September 2023 - Overcoming barriers to women accessing treatment for methamphetamine use – 18th October 2023 - Cannabis use among people with opioid use disorder – 20th November 2023 <p>Available on the NCCRED website</p>	<ul style="list-style-type: none"> - 22 attended / 115 views online - 13 attended / 104 views online - 32 attended / 7,049 views online - 40 attended / 60 views online - 33 attended / 87 views online - 47 attended / 161 views online - 43 attended / 167 views online - 46 attended / 278 views online - 56 attended / 211 views online - 85 attended / 792 views online - 47 attended / 177 views online - 55 attended / 98 views online <p>Total views 48,575</p>
<p>Three-part Clinical Research webinar series</p>	<ul style="list-style-type: none"> - Introduction to Evidence-Based Practice for clinicians in the AOD sector – Tuesday 2nd February 2021 - Introduction to Clinical Research for clinicians in the AOD sector – Tuesday 9th February 2021 - Introduction to Good Clinical Practice in Clinical Research (ICH-GCP E6 R(2)) for clinicians working in the AOD sector - Tuesday 16th February 2021 <p>Available on the NCCRED website</p>	<ul style="list-style-type: none"> - 52 attendees - 52 attendees - 26 people receiving Transcelerate-accredited GCP certification
<p>Adaptive Practices – A clinical & Community response to COVID-19 (continued series from 2019 – 2020)</p>	<ul style="list-style-type: none"> - Transitioning to telehealth: providing critical service at a distance – Friday 24th April 2020 - Worker wellbeing and best practice in AOD care – Friday 1st May 2020 - Micro skills for AOD professionals working from home – Friday 8th May 2020 - Real drug talk: connecting consumers in isolation – Friday 15th May 2020 - Supporting families as we shutdown – Friday 22nd May 2020 - Effects of isolation on the Aboriginal and Torres Strait Islander community – Friday 29th May 2020 - The Emerging Drug Network of Australia (EDNA) Project – Friday 12th June 2020 - Avoiding the drop zone: GHB use after isolation – Friday 19th June 2020 - COVID-19 and changes in key research cohorts – Friday 26th June 2020 - LGBTI Health: changes during COVID-19 – Friday 3rd July 2020 - General Practice: the frontline of the AOD sector & COVID-19 – Friday 10th July 2020 <p>Available on the NCCRED website</p>	<ul style="list-style-type: none"> - 320 views - 328 views - 157 views - 151 views - 69 views - 121 views - 117 views - 226 views - 72 views - 66 views - 87 views

<p>Alcohol and other Drug Telephone Counselling Toolkit (e-Learning modules)</p> <p>Developed with Insight: Centre for alcohol and other drug training and workforce development, and ADIS 24/7 Alcohol and Drug Support</p>	<p>Online training modules – available to access any time</p> <ul style="list-style-type: none"> - AOD Telephone Counselling 1: Foundational Concepts and Skills - AOD Telephone Counselling 2: Managing Complex Calls <p>Videos</p> <ul style="list-style-type: none"> - Telephone counselling tips for new workers - What are the challenges with telephone counselling? - What makes a call memorable? <p>Resources</p> <ul style="list-style-type: none"> - 5,4,3,2,1 Activity - Surfing the Urge Activity - SOBER Breathing Activity - Safe Space Activity <p>Available on the NCCRED website</p>	<p>Toolkit viewed 1223 times</p> <ul style="list-style-type: none"> - Module 1: 897 enrolments - Module 2: 580 enrolments <p>There was a 65% completion rate across both modules.</p> <p>There were enrolments across all states and territories with a few overseas enrolments.</p> <p>Learners identify from various work areas with majority from AOD sector 54% and Mental health 21%. 41% of learners worked for NGOs.</p> <p>In post-module evaluation, learners rated their overall satisfaction with the modules 90%.</p> <p>Videos</p> <ul style="list-style-type: none"> - 644 views - 444 views - 418 views <p>Resources</p> <ul style="list-style-type: none"> - 279 downloads - 595 downloads - 336 downloads - 183 downloads
<p>International Conference on Harmonisation for Good Clinical Practice (ICH-GCP E6) in Clinical Research. Transcelerate-accredited training for the AOD sector</p>	<ul style="list-style-type: none"> - ICH-GCP Refresher training June 2019 - ICH-GCP Full certification September 2019 - ICH-GCP Full certification February 2020 - ICH-GCP Full certification February 2021 - ICH-GCP Refresher training May 2022 - ICH-GCP Full certification August 2022 - ICH-GCP Full certification April 2022 - ICH-GCP Full certification March 2024 	<ul style="list-style-type: none"> - 5 attendees - 8 attendees - 16 attendees - 26 attendees - 9 attendees - 4 attendees - 8 attendees - 11 attendees
<p>Research Training Program for Scholarship recipients</p>	<p>Training included:</p> <ul style="list-style-type: none"> - ICH-GCP training; Tuesday 16th February 2021 	<p>3 attendees (NCCRED 2021 clinical research scholars and one PhD)</p>

	<ul style="list-style-type: none"> - Biostatistics; Thursday 3rd June 2021 - Australian research context; Thursday 27th May 2021 - Library resources (effective search strategies, Endnote, resource availability); Wednesday 19th May 2021. 	student)
Video Abstracts by NCCRED (NCCRED)	<ul style="list-style-type: none"> - GHB Cultures, Practices and Experiences Study – 29th March 2022 - Pharmacotherapies for Methamphetamine Withdrawal – 11th July 2022 - Lisdexamphetamine for the treatment of methamphetamine withdrawal: Safety and feasibility - the OLAM study – 6th February 2023 - Strengthening first line telephone support for people who use Methamphetamine – 12th April 2023 - The role of technology in therapy for methamphetamine use disorder – 24th April 2023 - The health & social characteristics of people who use methamphetamine in New South Wales – 26th June 2023 - Supporting healing on Nao and Barngarla Country – 23rd October 2023 - Exploring barriers to treatment-seeking with women who use methamphetamine – 8th March 2024 <p>Available on the NCCRED website</p>	<ul style="list-style-type: none"> - 4,593 views - 1,484 views - 13,144 views - 181 views - 208 views - 218 views - 202 views - 288 views - Total views 20,318

Appendix 5. Published outputs

Peer reviewed publications

Journal articles

Bonevski B, Jackson M, Austin E, Lintzeris N, **Ezard N**, Gartner C, Oldmeadow C, Haber P, Hallinan R, Rodgers C, Ho T, Nean M, Harrod M, Dunlop A. **HARMONY (HARM reduction for Opiates, Nicotine and You) Trial: Protocol of a Randomised Controlled Trial of the Effectiveness of Vaporised Nicotine Products for Tobacco Smoking Cessation amongst NSW Opiate Agonist Treatment Clients**. medRxiv 2024.06.21.24309014; doi: <https://doi.org/10.1101/2024.06.21.24309014>.

Oldmeadow C, Nolan E, Bonevski B, Jackson M, Lintzeris N, **Ezard N**, Gartner C, Haber P, Hallinan R, Rodgers C, Ho T, Dunlop A. **HARMONY (HARM reduction for Opiates, Nicotine and You): Statistical Analysis Plan for a Randomised Controlled Trial of the Effectiveness of Vaporised Nicotine Products for Tobacco Smoking Cessation amongst NSW Opiate Agonist Treatment Clients**. medRxiv 2024.06.21.24309282; doi: <https://doi.org/10.1101/2024.06.21.24309282>.

Heijstee N, Black E, Black E, Demirkol A, Mammen K, Mills L, Deacon R, **Ezard N**, Montebello M, Reid D, Bruno R, Shakeshaft A, **Siefried KJ**, Farrell M, Lintzeris N. **Sociodemographic and Health Factors of the Alcohol Treatment-seeking Population in New South Wales, Australia**. J Addict Med. 2024 Jun 3. doi: [10.1097/ADM.0000000000001311](https://doi.org/10.1097/ADM.0000000000001311). Epub ahead of print. PMID: 38828937.

Farooq A, Valerio H, Wheeler A, Martinello M, Henderson C, Silk D, Degenhardt L, Read P, Dore GJ, Grebely J, Cunningham EB, **ETHOS Engage Study Group**. **Needle and syringe sharing among people who have recently injected drugs in Australia: The ETHOS Engage Study**. Drug Alcohol Rev. 2024 May;43(4):1019-1028. doi: [10.1111/dar.13828](https://doi.org/10.1111/dar.13828). Epub 2024 Apr 17. PMID: 38630939.

Elkholy H, Tay Wee Teck J, Arunogiri S, Ramses Asaad M, Baessler F, Bhad R, Borghi EN, Busse A, Ekhtiari H, Dave S, Ferri M, Greene C, Koob GF, Kouimtsidis C, Krupchanka D, Nikendei C, Pipyrrou S, Poznyak V, Volkow ND, White AM, Khojasteh Zonoozi A, **Ezard N**, Potenza MN, Baldacchino AM. **Substance Use Disorders Among Forcibly Displaced People: a Narrative Review**. Curr Addict Rep 10, 341–352 (2023). <https://doi.org/10.1007/s40429-023-00467-6>.

Harris O, **Siefried KJ**, Chiew A, Jamshidi N, Chung DT, Moore N, Nic Ionmhain U, Roberts DM, **Ezard N**, Brett J. **Trends in reported GHB-related presentations to Sydney emergency departments between 2012 and 2021**. Emerg Med Australas. 2024 Aug;36(4):604-608. doi: [10.1111/1742-6723.14402](https://doi.org/10.1111/1742-6723.14402). Epub 2024 Apr 1. PMID: 38558322.

Acheson LS, Gordon C, McKetin R, Brett J, Christmas M, Rodgers C, Lintzeris N, Dunlop A, Farrell M, Shoptaw S, **Ezard N**, **Siefried KJ**. **Measuring Objective and Subjective Sleep during Lisdexamfetamine Treatment of Acute Methamphetamine Withdrawal: A Feasibility Study**. European Addiction Research. Published online March 18, 2024:1-5. doi:<https://doi.org/10.1159/000536328>.

Acheson LS, Clay S, McKetin R, Lintzeris N, Dunlop A, Brett J, Christmass M, Rodgers C, Shoptaw S, Farrell M, **Ezard N**, **Siefried KJ**. **Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention**. Int J Drug Policy. 2024 Apr;126:104383. doi: [10.1016/j.drugpo.2024.104383](https://doi.org/10.1016/j.drugpo.2024.104383). Epub 2024 Mar 12. PMID: 38479162.

Smith JL, Greene S, McCutcheon D, Weber C, Kotkis E, Soderstrom J, Douglas B, Lenton S, Grigg J, Dessauer P, **Ezard N**, Fatovich DM; EDNA Investigators. **A multicentre case series of analytically confirmed gamma-hydroxybutyrate intoxications in Western Australian emergency departments: Pre-hospital circumstances, co-detections and clinical outcomes**. Drug Alcohol Rev. 2024 May;43(4):984-996. doi: [10.1111/dar.13830](https://doi.org/10.1111/dar.13830). Epub 2024 Mar 1. PMID: 38426636.

Cheng Q, Valerio H, Cunningham EB, Shih STF, Silk D, Conway A, Treloar C, Murray C, Henderson C, Amin J, Read P, Dore GJ, Grebely J; **ETHOS Engage Study Group**. **Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study**. Value Health. 2024 Feb;27(2):216-225. doi: [10.1016/j.jval.2023.10.013](https://doi.org/10.1016/j.jval.2023.10.013). Epub 2023 Nov 10. PMID: 37951538.

Sharafi H, Bakouni H, McAnulty C, Drouin S, Coronado-Montoya S, Bahremand A, Bach P, **Ezard N**, Le Foll B, Schütz CG, **Siefried KJ**, Tardelli VS, Ziegler D, Jutras-Aswad D. **Prescription psychostimulants for the**

treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. *Addiction*. 2024 Feb;119(2):211-224. doi: 10.1111/add.16347. Epub 2023 Oct 25. PMID: 37880829.

Siefried KJ, Bascombe F, Clifford B, Liu Z, Middleton P, Kay-Lambkin F, Freestone J, Herman D, Millard M, Steele M, Acheson L, Moller C, Bath N, Ezard N. *Effect of a Smartphone App (S-Check) on Actual and Intended Help-Seeking and Motivation to Change Methamphetamine Use Among Adult Consumers of Methamphetamine in Australia: Randomized Waitlist-Controlled Trial.* *JMIR Mhealth Uhealth*. 2024 Jul 3;12:e55663. doi: 10.2196/55663. PMID: 38959499; PMCID: PMC11255525.

Greene MC, Busse A, Ventevogel P, Kane J, **Ezard N.** *Moving from feasible to essential: Progress and future directions for promoting the implementation of substance use services for forcibly displaced populations in humanitarian settings.* *Addiction*. 2024 Mar;119(3):408-410. doi: 10.1111/add.16386. Epub 2023 Nov 15. PMID: 37968774; PMCID: PMC11176524.

Bascombe F, Siefried KJ, Clifford B, Child S, Loos R, Sgouras H, Stevens L, Wilson H, Ezard N. *Methamphetamine and emerging drugs of concern: A training needs analysis of Australian alcohol and other drug helplines.* *Drug Alcohol Rev*. 2023 Nov;42(7):1744-1753. doi: 10.1111/dar.13719. Epub 2023 Jul 15. PMID: 37452757.

Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, Le Foll B, Schütz CG, Tardelli V, **Ezard N, Siefried K, Jutras-Aswad D.** *Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.* *Drug Alcohol Depend*. 2023 Dec 1;253:111018. doi: 10.1016/j.drugalcdep.2023.111018. Epub 2023 Nov 4. PMID: 37979478.

Sivak L, Reilly R, Lockton J, Treloar C, Roe Y, McKetin R, Butt J, **Ezard N, Winkenweder H, Ward J.** *Psychosocial stress and methamphetamine use: A mixed-methods study of intersectional stigma and Aboriginal and Torres Strait Islander methamphetamine use.* *Int J Drug Policy*. 2023 Nov;121:104189. doi: 10.1016/j.drugpo.2023.104189. Epub 2023 Sep 13. PMID: 37708599.

Black E, Bruno R, Mammen K, Mills L, **Siefried KJ, Deacon RM, Shakeshaft A, Dunlop AJ, Ezard N, Montebello M, Childs S, Reid D, Holmes J, Lintzeris N.** *Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study.* *Med J Aust*. 2023 Sep 4;219(5):218-226. doi: 10.5694/mja2.52039. Epub 2023 Jul 14. PMID: 37449648.

Freestone J, Ezard N, Bourne A, Brett J, Roberts D, Hammoud M, Nedanoski A, Prestage G, Siefried KJ. *Understandings, attitudes, practices and responses to GHB overdose among GHB consumers.* *Harm Reduction Journal*. 2023;20(1). doi:https://doi.org/10.1186/s12954-023-00857-z.

Wand H, Reilly R, McKetin R, Quinn B, Roe Y, Conigrave K, **Ezard N, Butt J, Treloar C, Sivak L, Shackelford I, Dunlop A, Ward J.** *Investigating associations between methamphetamine use, mental health and risky sexual behaviours amongst Aboriginal and Torres Strait Islander peoples.* *Mental Health & Prevention*. 2023;30:200267. doi:https://doi.org/10.1016/j.mhp.2023.200267.

Clifford B, Van Gordon K, Magee F, Malone V, Siefried KJ, Graham D, Ezard N. *"There's a big tag on my head": exploring barriers to treatment seeking with women who use methamphetamine in Sydney, Australia.* *BMC Health Services Research*. 2023;23(1). doi:https://doi.org/10.1186/s12913-023-09125-z.

Aung HL, **Siefried KJ, Gates TM, Brew BJ, Mao L, Carr A, Cysique LA.** *Meaningful cognitive decline is uncommon in virally suppressed HIV, but sustained impairment, subtle decline and abnormal cognitive aging are not.* *EClinicalMedicine*. eCollection 2023 Feb.

Black E, Mammen K, Deacon RM, **Ezard N, Mills L, Dunlop AJ, Montebello M, Reid D, Childs S, Bruno R, Shakeshaft A, Siefried KJ, Farrell M, Holmes J, Lintzeris N.** *Health and social characteristics of clients reporting amphetamine type substance use at entry to public alcohol and other drug services in New South Wales, Australia, 2016-2019.* *Drug Alcohol Rev*. 2023 Feb;42(2):389-400. doi: 10.1111/dar.13588. Epub 2022 Dec 16. Erratum in: *Drug Alcohol Rev*. 2023 Nov;42(7):1860-1861. doi: 10.1111/dar.13731. PMID: 36524444; PMCID: PMC10107800.

Siefried KJ, Freeman G, Roberts DM, Lindsey R, Rodgers C, Ezard N, Brett J. *Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: a retrospective medical record review.* *Psychopharmacology* 2023;240(1):127-135.

Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M,

Shoptaw S, Siefried KJ. **Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial.** Drug Alcohol Dependence 241:109692.

Freeman G, Siefried KJ, Roberts DM, Rodgers C, Nic Ionmhain U, Ramanathan J, Ezard N, Brett J. **Phenobarbital to manage severe gamma-hydroxybutyrate withdrawal: A case series.** Drug Alcohol Rev. 2023; 42(1):27-32.

Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. **Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal.** PLoS One. 17(10):e0275371.

Acheson LS, Williams BH, Farrell M, McKetin R, Ezard N, Siefried KJ. **Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials.** Drug Alcohol Rev. 2023;42(1):7-19.

Miller P, Vakidis T, Taylor N, Baker T, Stella J, Egerton-Warburton D, Hyder D, Staiger P, Bowe SJ, Shepherd J, Zordan R, Walby A, Lloyd Jones M, Caldicott D, Barker D, Hall M, Doran CM, Ezard N, Preisz P, Havard A, Shakeshaft A, Akhlaghi H, Kloot K, Lowry N, Bumpstead S. **Most common principal diagnoses assigned to Australian emergency department presentations involving alcohol use: A multi-centre study.** Aust N Z J Public Health. 2022; 46(6):903-9.

Freestone J, Bourne A, Layard E, Prestage G, Murray J, Siefried KJ. **Playing at the edges, navigating sexual boundaries, and narrating sexual distress; Practices and perspectives of sexuality and gender diverse people who use GHB.** Int J Drug Policy. 2022;108:103811.

Freestone J, Siefried KJ, Prestage G, Hammoud M, Molyneux A, Bourne A. **Individual level peer interventions for gay and bisexual men who have sex with men between 2000 and 2020: A scoping review.** PLoS One. 2022;17(7):e0270649.

Freestone J, Prestage G, Bourne A, Ezard N, Race K, Nedanoski A, Murray J, Siefried KJ. **Controlling for pleasure and risk: The experiences of sexuality and gender diverse people who use GHB.** Int. J. Drug Policy. 2022; 105:103747. DOI: 10.1016/j.drugpo.2022.103747.

Brener L, Caruana T, Broady T, Cama E, Ezard N, Madden A, Treloar C. **Addressing injecting related risks among people who inject both opioids and stimulants: Findings from an Australian survey of people who inject drugs.** Addict. Behav. Rep. 2022; 15:100398. DOI: 10.1016/j.abrep.2021.100398.

Smith JL, Soderstrom J, Dawson A, Alfred S, Greene S, Isoardi K, McCutcheson D, Oosthuizen F, Ezard N, Burcham J, Fatovich DM, EDNA Investigators. **The Emerging Drugs Network of Australia: A toxicosurveillance system of illicit and emerging drugs in the emergency department.** EMA. 2022; 34(1):58-64. DOI: 10.1111/1742-6723.13839.

Conigrave JH, Wilson S, Conigrave KM, Chikritzhs T, Hayman N, Dawson A, Ali R, Perry J, Fitts MS, Degenhardt L, Doyle M, Egert S, Slade T, Ezard N, Dzidowska M, Lee KS. **'The Drug Survey App': a protocol for developing and validating an interactive population survey tool for drug use among Aboriginal and Torres Strait Islander Australians.** Addict Sci Clin Pract. 2022; 17(1):17. DOI: 10.1186/s13722-022-00298-2.

Page R, Healey A, Siefried KJ, Harrod ME, Franklin E, Peacock A, Barratt MJ, Brett J. **Barriers to help-seeking among music festival attendees in New South Wales, Australia.** Drug Alcohol Rev. 2022; doi: 10.1111/dar.13479.

Black E, Monds LA, Chan B, Brett J, Hutton JE, Acheson L, Penm J, Harding S, Strumpman D, Demirkol A, Lintzeris N. **Overdose and take-home naloxone in emergency settings: a pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.** Emergency Medicine Australasia. 2022 Aug;34(4):509-18.

Siefried KJ, Ezard N, Christmass M, Haber P, Ali R; NCCRED Methamphetamine and Emerging Drugs Clinical Research Network Working Group. **A clinical research priority setting study for issues related to the use of methamphetamine and emerging drugs of concern in Australia.** Drug Alcohol Rev. 2022 Feb;41(2):309-319. doi: 10.1111/dar.13350. Epub 2021 Jul 8. PMID: 34237176; PMCID: PMC9290984.

Hill P, Stoope M, Agius PA, Maher L, Hickman M, Crawford S, Dietze P. **Mortality in the SuperMIX cohort of people who inject drugs in Melbourne, Australia: A prospective observational study.** Addiction, accepted 30 May 2022.

Ezard N, Clifford B, Dunlop A, Bruno R, Carr A, Liu Z, **Siefried KJ**, Lintzeris N. **Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study**. *BMJ Open*. 2021; 11, pp. e044696.

Peacock A, Gibbs D, Price O, Barratt MJ, **Ezard N**, Sutherland R, **Hill PL**, Grigg J, Lenton S, Page R, Salom C, Hughes C, Bruno R. **Profile and correlates of colorimetric reagent kit use among people who use ecstasy/MDMA and other illegal stimulants in Australia**. *Int J Drug Policy*. 2021; (97), pp 103334 DOI: <https://doi.org/10.1016/j.drugpo.2021.103334>.

Acheson LS, **Siefried KJ**, Clifford B, Murray E, Steele M, Clague L, Malone V, Roberts DM, Ferguson LJ, Matthews GV, **Ezard N**. **One-third of people who inject drugs are at risk of incomplete treatment for staphylococcus aureus bacteremia: a retrospective medical record review**. *Int J Infect Dis*. 2021; 12(63-5) DOI: [10.1016/j.ijid.2021.09.012](https://doi.org/10.1016/j.ijid.2021.09.012).

Lee E, Mao L, de Wit J, Rule J, Carr A, **Siefried KJ**, on behalf of the PAART study investigators. **Impact of the removal of patient co-payments for antiretroviral therapy (ART) on out-of-pocket expenditure, adherence and virological failure among Australian adults living with HIV**. *Health Policy*. 2021; DOI: <https://doi.org/10.1016/j.healthpol.2021.07.002>.

Brett J, **Siefried KJ**, Healey A, Harrod ME, Franklin E, Barratt MJ, Masters J, Nguyen L, Adiraju S, Gerber C. **Wastewater analysis for psychoactive substances at music festivals across New South Wales, Australia in 2019-2020**. *Clin Toxicol*. 2021; DOI:10.1080/15563650.2021.1979233.

Greene MC, Haddad S, Busse A, **Ezard N**, Ventevogel P, Demis L, Inoue S, Gumm JC, Campello G, Tol WA, Kane JC. **Priorities for addressing substance use disorder in humanitarian settings**. *Confl Health*. 2021; 15(1):71. DOI: [10.1186/s13031-021-00407](https://doi.org/10.1186/s13031-021-00407)

Healey A, **Siefried KJ**, Harrod ME, Franklin E, Peacock A, Barratt MJ, Brett J. **Correlates of higher-risk drug-related behaviours at music festivals in New South Wales, Australia**. *Drug Alcohol Rev*. 2021; DOI: [10.1111/dar.13404](https://doi.org/10.1111/dar.13404)

Peacock A, Gibbs D, Price O, Barratt MJ, **Ezard N**, Sutherland R, **Hill PL**, Grigg J, Lenton S, Page R, Salom C, Hughes C, Bruno R. **Profile and correlates of colorimetric reagent kit use among people who use ecstasy/MDMA and other illegal stimulants in Australia**. *The International journal on drug policy*, 97, 103334. <https://doi.org/10.1016/j.drugpo.2021.103334>

Smith JL, Soderstrom J, Dawson A, Alfred S, Greene S, Isoardi K, McCutcheon D, Oosthuizen F, **Ezard N**, Burcham J, Fatovich DM, on behalf of the EDNA Investigators. **The emerging drugs network of Australia: a toxicosurveillance system of illicit and emerging drugs in the emergency department**. *Emerg Med Australas*. 2021; DOI:10.1111/1742-6723.13839.

Lewer D, Jones N, Hickman M, Larney S, **Ezard N**, Nielsen S, Degenhardt L. **Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: a cohort study and nested crossover-cohort analysis**. *Drug Alcohol Depend*; 2020, 108343, DOI: <https://doi.org/10.1016/j.drugalcdep.2020.108343>.

Book Chapters

Ezard N, Manji H, Busse A. Substance use among populations displaced by conflict. In el-Guebaly N, Galanter M, Carra G (eds): *The Textbook of Addiction Treatment: International Perspectives* (Second Ed). Springer, 2021.

Reports

Bascombe F, **Siefried KJ**, Clifford B, Middleton P, Liu Z, Wilson J, Kay-Lambkin F, **Ezard N**. **Feasibility and efficacy of the S-Check App, a mobile Health (mHealth) early-intervention tool to change help seeking behaviour of people who use methamphetamine: A randomised wait-list controlled trial**. Report prepared for NSW Health Government, 2021.

Conference Presentations

Acheson L, McKetin R, **Ezard N**, Lintzeris N, Brett J, Rodgers C, Christmass M, Gill A, Farrell M, Dunlop A,

Shoptaw S, Siefried KJ. **Participant experiences in a pilot study for methamphetamine withdrawal treatment: Implications for retention.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Atefi D, Ashworth G, Auld R, Brouwer I, Buckley N, Chan T, Cretikos M, Cullinan U, Dawson A, Dunlop AJ, Ezard N. **Collaborative surveillance and public health responses to illicit and emerging drugs in New South Wales.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Bolton A, Spooner C, Ezard N, Harris M. **Barriers and enablers to caring for people who regularly use methamphetamine-Sydney general practitioner perspectives.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Knock E, Ezard N, Day R, Siefried KJ, Liknaitzky P, Ross M, Albert S, Brett J. **Psilocybin-assisted psychotherapy for methamphetamine use disorder: Recruitment to a novel safety and feasibility trial.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Lee KS, Wilson S, Perry J, Conigrave JH, Zheng C, Dale L, Dzidowska M, Ali R, Ezard N, Conigrave KM. **Tailored brief interventions and flexible content management systems: To enable the Grog App to be adapted across language and context.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Moller C, Siefried KJ, Clifford B, Acheson L, Brett J, Dunlop A, Haber P, Christmass M, Lintzeris N, Morley K, Shoptaw S, Trivedi M, Ezard N. **Oral naltrexone-bupropion combination pharmacotherapy for methamphetamine use disorder: Pilot study protocol.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Morrison E, Gough C, Stowe MJ, Jauncey M, Ezard N, Henderson C, Ritter A, Nielsen S. **Symposium: Safe (r) access for an Australian context: Starting a conversation.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Walker M, Peacock A, Lang R, Stirling R, van der Sterren A, Crossin R, Ezard N, Dunne J. **Alcohol and other drug policy and the role of research in driving reform.** Presented at the Australasian Professional Society on Alcohol and other Drugs Annual Scientific Conference, Adelaide, Australia, 12-15 November 2023.

Siefried KJ, Clifford B, Acheson L, Ezard N. **Innovations beyond BC: Lisdexamfetamine for the treatment of methamphetamine use disorder and withdrawal.** Presented at the 5th Annual BC Substance Use Conference, Vancouver, Canada, 20-23 April 2023.

Buhagiar K, Brett J, Siefried KJ. **GHB Cultures, practices, and experiences: A qualitative study exploring diverse cultures, practices and experiences of GHB use among cisgender or transgender people who identify as heterosexual and live in Australia.** Presented at Harm Reduction International, Melbourne, Australia, 16-20 April 2023.

Hill P, Clifford B, Brown J, Dessauer P, Oh G, Lyons T, Herbert A, McKinnon G, Lamb M, Crawford S, Mason C, Siefried KJ, Ezard N. **Strength in solidarity: Bringing together diverse local stakeholders to disseminate public drug information (presented on behalf of the Prompt Response Network).** Presented at Harm Reduction International, Melbourne, Australia, 16-20 April 2023.

McVinish A, Steele M, McIver R, Latimer J, Clifford B, Siefried KJ. **Help wanted: Recruiting and leading nurses in the setup of Australia's first supervised injectable opioid treatment clinic.** Presented at Harm Reduction International, Melbourne, Australia, 16-20 April 2023.

Acheson LS, Gordon C, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. **An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial.** Presented at the Lisbon Addictions Conference, Lisbon, Portugal, 23-25 November 2022.

Bascombe F, Siefried KJ, Clifford B, Middleton P, Liu Z, Wilson J, Steele M, Kay-Lambkin F, Ezard N. **Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine.** Presented at the Lisbon Addictions Conference, Lisbon, Portugal, 23-25 November 2022.

Ezard N. **Psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?** Chair Great Debate at the Lisbon Addictions Conference, Lisbon, Portugal, 23-25 November 2022.

Ezard, N. Substance Use Among Populations Displaced by Conflict: Assessments, Findings, Recommendations. Presented at the Lisbon Addictions Conference, Lisbon, Portugal, 23-25 November 2022.

Hill P, Elliott M, Cave T, Tzanetis S, Siefried KJ, Lenton S, Ezard N. Co-designing an Australian Prompt Response Network. Presented at the Lisbon Addictions Conference, Lisbon, Portugal, 23-25 November 2022.

Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial. Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022.

Bascombe F, Siefried KJ, Clifford B, Child S, Loos R, Sgouras H, Stevens L, Wilson H, Ezard N. A Training Needs Analysis for Alcohol and other Drug Telephone helplines for calls relating to Methamphetamine and Emerging drugs of concern. Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022.

Ezard N, on behalf of LiMA investigators. The LiMA study: Safety and tolerability of lisdexamfetamine for methamphetamine dependence. Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022.

Hill P on behalf of the Prompt Response Network. Implementing The Prompt Response Network. Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022

Knock E, Ezard N, Day R, Siefried KJ, Likhaitzky P, Ross M, Albert S, Brett, J. Psilocybin facilitated treatment for Methamphetamine use disorder: A Pilot Study (Psi-MA). Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022.

Mills L, Black E, Deacon R, Dunlop AJ, Ezard N, Bruno R, Shakeshaft A, Farrell M, Holmes J, Cretikos M, Montebello M, Reid D, Childs S, Siefried K, Mammen K and Lintzeris N. Impact of Amphetamine Type Stimulant Use on Clinical Outcomes in OTP Clients. Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022.

Peacock A, Sutherland R, Bruno R, Barratt M, Keygan J, Ezard N, Hill P, King C, Brown J, Page R, Lenton S, Dietze P, Salom C, Sumnall H, Harrod M. Risk communication for people who use drugs: Awareness of, behavioural responses to, and preferences for, dissemination of drug alerts. Presented at NCCRED Symposium: Transforming healthcare responses to methamphetamine and emerging drugs. Presented at the National Centre for Clinical Research on Emerging Drugs Annual Symposium, Canberra, Australia, 7 November 2022.

Ezard N, Clifford B, Siefried KJ, Acheson L. Safety and tolerability of lisdexamfetamine for methamphetamine dependence and withdrawal, early experience from Australia: The LiMA Trial and OLAM pilot. Presented at the Annual Meeting & Conference of the Norwegian Association for Addiction Medicine, Bergen, Norway, 31 October - 2 November 2022. (Virtual attendance)

Acheson LS, Ezard N, Lintzeris N, Dunlop AJ, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial. Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Black E, Mammen K, Deacon RM, Mills L, Montebello M, Bruno R, Dunlop AJ, Ezard N, Shakeshaft A, Farrell M, Holmes J, Reid D, Childs S, Siefried KJ, Lintzeris N. Clients entering New South Wales alcohol and other drug treatment services: Characteristics by principal drug of concern, July 2016-June 2019. Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Clifford B, Acheson LS, Brener L, Siefried KJ, Steele M, Matthews G, Ezard N. A qualitative exploration of client and healthcare provider perspectives on why people who inject drugs with injecting-related infections discharge against medical advice. Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Clifford B, Shine P, Lo N, Stockwell T, Haber PS, Baldry E, Day CA, Dobbins T, Peacock A, Pauly B, Lintzeris N, Dolan K, Macklin B, Siefried KJ, Brett J, Dunlop AJ, Ezard N. The AusMAP study: A protocol for a randomised, controlled feasibility study of a managed alcohol program in Australia, Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Freeman G, Siefried KJ, Roberts DM, Rodgers C, Ionmhain UN, Ramanathan J, Ezard N, Brett J. **Phenobarbital to manage severe gamma hydroxybutyrate withdrawal: A case series.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Freestone J, Ezard N, Brett J, Roberts DM, Murray J, Prestage G, Hammoud M, Siefried KJ. **“Sometimes I have a duty of care not to call 000”: Reported practices, attitudes and factors influencing consumer responses to GHB overdose.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Hill P, Siefried KJ, Tzanetis S, Peacock A, Lenton S, Ezard N, on behalf of the Prompt Response Network. **An Australian National Prompt Response Network for Emerging Drugs.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Knock E, Ezard N, Day R, Siefried KJ, Likhaitzky P, Ross M, Albert S, Brett J. **A study protocol for the PsiMA trial: Psilocybin assisted psychotherapy for methamphetamine use disorder.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Mills L, Mammen K, Deacon RM, Black E, Montebello M, Bruno R, Dunlop AJ, Ezard N, Shakeshaft A, Farrell M, Holmes J, Reid D, Childs S, Siefried KJ, Lintzeris N. **Outcomes for clients in opioid treatment programs who use amphetamine type substances: Results from a retrospective analysis of routinely-collected clinical data.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Reilly R, McKetin R, Butt J, Ezard N, Dunlop AJ, Conigrave K, Quinn B, Treloar C, Gray D, Sivak L, Lockton J, Whetham H, Ward J. **Lessons from the evaluation of a novel web-app to assist Aboriginal and Torres Strait Islander people to reduce or stop using methamphetamine: We Can Do This.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022. <https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.13537>

Siefried KJ, Freeman G, Roberts DM, Lindsey R, Rodgers C, Ezard N, Brett J. **Inpatient GHB withdrawal management in an inner-city hospital in Sydney, Australia: A retrospective medical record review.** Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Ezard N. **Clinical research in the treatment of methamphetamine use disorder – where are we now and where are we going?** keynote, International Society of Addiction Medicine, Valetta, Malta, 4-7 October 2022

Ezard N, Clifford B, Siefried K., on behalf of LiMA investigators **Safety and tolerability of oral lisdexamfetamine for methamphetamine dependence.** Presented at International Society of Addiction Medicine, Valetta, Malta, 4-7 October 2022

Acheson LS, Ezard N, Lintzeris N, Dunlop AJ, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. **Lisdexamfetamine for the treatment of acute methamphetamine withdrawal.** Invited speaker, National Drug and Alcohol Research Centre Annual Symposium, Sydney Australia, 20-21 September 2022.

Acheson LS, Ezard N, Lintzeris N, Dunlop AJ, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. **Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot safety and feasibility trial.** St Vincent's Hospital Sydney Research week, Sydney Australia, 19-21 September 2022.

Bascombe F, Siefried KJ. **The methamphetamine treatment landscape.** Presented at DANA Conference, Adelaide, Australia, 4-5 August 2022.

Bascombe F, Buckley J, Deifel-Carlino H, Siefried KJ. **Transition to telephone-based care: Developing the AOD Telephone Counselling Toolkit.** Presented at DANA Conference, Adelaide, Australia, 4-5 August 2022.

Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried K. **The Safety and Feasibility of Lisdexamfetamine for the Treatment of Acute Methamphetamine Withdrawal: Preliminary Results of an Open Label Pilot Study.** Presented at the College on Problems of Drug Dependence (CPDD), 84th Annual Scientific Meeting, Minneapolis USA, 11-15 June 2022 (virtual).

Siefried K, Acheson L, Williams B, Farrell M, McKetin R, Ezard N. **Outcomes and measures used in randomised controlled trials examining pharmacotherapies for the treatment of methamphetamine withdrawal: results of a systematic review.** Presented at the College on Problems of Drug Dependence

(CPDD), 84th Annual Scientific Meeting, Minneapolis USA, 11-15 June 2022 (virtual).

Williams BH, **Acheson LS**, Farrell M, McKetin R, **Ezard N**, **Siefried K**. **Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials**. Presented at RANZCP Congress, Sydney, 15-19 May 2022. <http://dx.doi.org/10.1177/00048674221088686>.

Hill P. Prompt Response Network. Presented at Toxicology and Poisons Network Australasia Conference, 11-13 May 2022.

Aung HL, Gates TM, Mao L, Brew B, **Siefried KJ**, Carr A, Cysique L. **Abnormal cognitive aging is detected despite clinically defined cognitive stability**. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI), 14-16 Feb 2022 (virtual).

Acheson LS, Williams BH, Farrell M, McKetin R, **Ezard N**, **Siefried KJ**. **Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials**. Presented at NCCRED Symposium: Improving Outcomes - Interventions, Networks & Pharmacotherapies, 19 November 2021 (virtual).

Bascombe F, **Siefried KJ**, **Clifford B**, Middleton P, Liu Z, Wilson J, Kay-Lambkin F, **Ezard N**. **Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine**. Presented at NCCRED Symposium: Improving Outcomes - Interventions, Networks & Pharmacotherapies, 19 November 2021 (virtual).

Hill, P. **Towards an Australian Prompt Response Network for Emerging Drugs**. Presented at NCCRED Symposium: Improving Outcomes - Interventions, Networks & Pharmacotherapies, 19 November 2021 (virtual).

Reilly R, McKetin R, Butt J, Roe Y, **Ezard N**, Quinn B, Nagle J, Longbottom W, Treloar C, Warrior C, Hammersley D, Ward J, on behalf of the other NIMAC investigators and partner sites. **An acceptability and feasibility study of the We Can Do This online therapeutic program in primary care and residential rehabilitation settings**. Presented at NCCRED Symposium: Improving Outcomes - Interventions, Networks & Pharmacotherapies, 19 November 2021 (virtual). <https://nccred.org.au/collaborate/symposium/symposium-2019-2022>.

Black E, Monds L, Chan B, Brett J, **Acheson LS**, Hutton J, Penm J, Demirkol A, Lintzeris N. **The ONE Study (Overdose and take-home Naloxone in Emergency settings): A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' supply in emergency department settings**. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Dunlop AJ, White B, Roberts J, Graham R, **Ezard N**, Maher L, McEntyre E, Doyle M, Kypri K, Lintzeris N, Haber PS. **Understanding how long-active depot buprenorphine impacts the high-risk post-release period – protocol for the RELEASE study**. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Ezard N, Dunlop AJ, Liaw W, McDonough M, Ali R, White J, McKetin R, Bruno R, Carr A, Gill A, Rodgers C, Montebello M, Farrell M, Heinzerling K, Haber PS, Lubman DI, Graham R, Lintzeris N. **Covid and the LiMA study, a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence**. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Healey A, **Siefried KJ**, Harrod ME, Franklin E, Peacock A, Barratt MJ, Brett J. **Correlates of higher risk drug related behaviours at music festivals in New South Wales, Australia**. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Page RMS, Healey A, **Siefried KJ**, Harrod ME, Franklin E, Barratt MJ, Peacock A, Brett J. **Barriers to seeking help among music festival attendees in New South Wales, Australia**. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Siefried KJ, McKetin R, Bedi G, Brett J, Arunogiri S, Dunlop AJ, Lintzeris N, **Ezard N**. **Symposium: An update on pharmacotherapy trials for substance use disorder – methamphetamine type and withdrawal in Australia**. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Siefried KJ, Arunogiri S, Brett J, McKetin R, **Acheson LS**, Knock E, Farrell M, Dunlop AJ, Lintzeris N, **Ezard N**. *The future of pharmacotherapy clinical trials in Australia: the OLAM trial, the MOXY trial, the PsIMA trial, the TINA trial*. Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Acheson LS, **Ezard N**, Dunlop A, Lintzeris N, Brett J, Farrell M, McKetin R, Rodgers C, Gill A, Christmass C, Shoptaw S, **Siefried KJ**. *Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: Protocol and preliminary data*. Presented at NDARC Annual Symposium, 20-22 October 2021 (virtual).

Ezard N. *LiMA (RCT of lisdexamfetamine for the treatment of methamphetamine dependence)*. Presented at NDARC Annual Symposium, 20-22 October 2021 (virtual).

Bascombe F, **Siefried KJ**, **Clifford B**, Middleton P, Liu Z, Wilson J, Kay-Lambkin F, **Ezard N**. *Feasibility and efficacy of the S-Check App to change help seeking behaviour of people who use methamphetamine*. Presented at St Vincent's Research Symposium, 11-14 October 2021 (virtual).

Bascombe F, Stearne A, Bullen L. *An Introduction to Evidence-Based Practice and Clinical Research*. Presented at NIDAC Annual Conference, Adelaide, Australia, 23-26 March 2021.

Freestone J, **Siefried KJ**, Bourne A, Hammoud M, Prestage G. *Peer-led interventions addressing health and wellbeing for gay and bisexual men between 2000 and 2020: a scoping review*. Presented at Joint Australasian Sexual Health, HIV, and AIDS Conferences, 6-9 September 2021 (virtual).

Ezard N, **Siefried KJ**, **Acheson L**. *Treatment of methamphetamine dependence and withdrawal*. Presented at NIDA CTN Stimulant Research Task Force mini-symposium, 2 December 2020 (virtual).

Siefried KJ, **Acheson L**, Lintzeris N, **Ezard N**. *Clinical outcomes and measures used in randomised controlled trials examining pharmacotherapy for methamphetamine dependence*. Presented at NCCRED Clinical Research Symposium, 20 November 2020 (virtual).

Ezard, N. *Addressing substance use disorders and associated health and social consequences in humanitarian settings*. Presented at UNODC Expert Meeting, 8-10 September 2020 (virtual).

Black E, Deacon R, Mills L, Dunlop AJ, **Ezard N**, Bruno R, Shakeshaft A, Farrell M, Holmes J, Cretikos MA, Montebello M, Reid D, Childs S, **Siefried KJ**, Mammen K, Lintzeris N. *Characteristics and treatment outcomes of the drug treatment population in New South Wales: focus on amphetamine-type stimulants*. Presented at NCCRED Symposium: Collaborate, Generate, Translate - Research meets clinical practice in methamphetamine and emerging drugs, Hobart, Australia, 10 November 2019. <https://nccred.org.au/collaborate/symposium/symposium-2019-2022/>

Black E, Deacon R, Mills L, Dunlop AJ, **Ezard N**, Bruno R, Shakeshaft A, Farrell M, Holmes J, Cretikos MA, Montebello M, Reid D, Childs S, **Siefried KJ**, Mammen K, Lintzeris N. *Characteristics and treatment outcomes of the drug treatment population in New South Wales: focus on amphetamine type stimulants*. Presented at APSAD Annual Scientific Conference, Hobart, Australia, 10-13 November 2019. <https://onlinelibrary.wiley.com/doi/epdf/10.1111/dar.12991>

Conference Posters

Hill P. Prompt Response Network. *Towards an Australian National Prompt Response Network for Emerging Drugs*. Presented at the IX International Conference on Novel Psychoactive Substances (NPS), Panama, 24-26 October 2022.

Acheson LS, Gordon C, **Ezard N**, Lintzeris N, Dunlop AJ, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, **Siefried KJ**. *An exploratory analysis of actigraphy and sleep diaries in a methamphetamine withdrawal clinical trial*. Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

Bascombe F, **Siefried KJ**, **Ezard N**. *Strengthening first-line support for Australians who use drugs, their friends and families: A training needs analysis for alcohol and other drug helplines for calls relating to methamphetamine and emerging drugs of concern*. Presented at APSAD Scientific Alcohol and Drugs Conference, Darwin Australia, 9-12 October 2022.

May R, Ezard N, Siefried KJ, Bruno R. **Neurocognitive changes in adults with methamphetamine dependence treated with lisdexamfetamine compared with those with additional positive screening for childhood ADHD.** Presented at International Medicine in Addiction Conference, 26-28 February 2021 (virtual).

Acheson LS, Williams BHM, Farrell M, McKetin R, Ezard N, Siefried KJ. **Pharmacological treatment for methamphetamine withdrawal: a systematic review and meta-analysis of randomised controlled trials.** Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Black E, Deacon RM, Mills L, Mammen K, Dunlop AJ, Ezard N, Montebello M, Bruno R, Shakeshaft A, Farrell M, Holmes J, Reid D, Siefried KJ, Cretikos M, Lintzeris N. **Starting treatment in public drug and alcohol withdrawal services in New South Wales: what can electronic medical records tell us about amphetamine type stimulant use?** Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Heijstee N, Black E, Black E, Demirkol A, Mills L, Deacon RM, Mammen K, Dunlop AJ, Ezard N, Montebello M, Reid D, Childs S, Lintzeris N. **Who we are helping: describing demographic, health and social factors associated with principal drug of concern, alcohol use and alcohol-related harms, in the Australian alcohol and other drug treatment-seeking population.** Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Jackson MA, Austin EK, Lintzeris N, Ezard N, Gartner C, Oldmeadow C, Searles A, Nean M, Harrod ME, McLennan J, Haber PS, Gill A, Graham R, Ho T, Hallinan R, Dunlop AJ, Bonevski B. **Can e-cigarettes assist opiate agonist treatment clients to quit smoking? Methods and recruitment data.** Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Siefried KJ, Acheson LS, Dunlop AJ, Lintzeris N, Christmass M, Bonomo Y, Arunogiri S, Hayllar J, Ezard N, on behalf of study investigators. **A clinical research network approach to a trial of oral lisdexamfetamine for the treatment of acute methamphetamine withdrawal.** Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Siefried KJ, Ezard N, Christmass M, Hayllar J, Ali R, on behalf of the NCCRED methamphetamine and emerging drugs clinical research network working group. **Towards an Australian clinical research network for methamphetamine and emerging drugs – outcomes of the national centre for clinical research on emerging drugs methamphetamine and emerging drugs clinical research network working group 2018-21.** Presented at APSAD Annual Scientific Conference, 8-10 November 2021 (virtual). Drug Alcohol Rev. 2021; 40(Suppl 1): S4-S154. DOI: 10.1111/dar.13384.

Community publications

Lee, S - contributions by Siefried KJ, Baird S. **A future in digital?** The NADA Advocate (print publication). December 2022. <https://nada.org.au/wp-content/uploads/2022/12/NADA-advocate-2022-december.pdf>

Siefried KJ. **Emerging evidence for AOD workers.** The NADA Advocate (print publication). December 2022. <https://nada.org.au/wp-content/uploads/2022/12/NADA-advocate-2022-december.pdf>

Community presentations

Name	Presenter	Presented at	Date	Attendees
PRN	Penny Hill	United Nations Office of Drugs and Crime (UNODC), Vienna, Austria	21 September 2022	4
PRN overview	Penny Hill	Penington Institute Harm Reduction Meeting – Victorian Harm Reduction Sector	26 October 2022	35
Methamphetamine and Sleep	Liam Acheson Nadine Ezard	Cracks in the Ice	23 November 2023	194

Appendix 6. Roll of Mentors and Mentees

Mentee (role)	Mentor	Partner Organisation
Dr Andrew Kozman (Fellow)	Prof Simon Lenton (Director)	Curtin University (NDRI)
Dr Edward Mullen (Fellow)	Dr Bronwyn Milne (Paediatrician and Medicine Specialist)	Westmead Children's Hospital
Dr Adam Rubenis (Fellow)	Prof Katherine Mills (Director of Early Intervention and Treatment Research)	University of Sydney (The Matilda Centre for Research in Mental Health and Substance Use)
Dr Adam Rubenis (Fellow)	Prof Amanda Baker (NHMRC Senior Research Fellow & Clinical Psychologist)	University of Newcastle
Dr Elizabeth Knock (Scholar)	A/Prof Gill Bedi (Head, Substance Use Research)	Orygen The National Centre of Excellence in Youth Mental Health
Dr James Gooden (Scholar)	A/Prof Raimondo Bruno (Associate Professor in Psychology)	University of Tasmania
Mr Jason Ramp (Scholar)	Rachel Reilly (Senior Research Fellow)	South Australian Medical Research Institute
Dr Buddhima Lokuge (Grant recipient)	A/Prof Nadine Ezard (Director)	National Centre for Clinical Research on Emerging Drugs
Dr Robert Page (Grant recipient)	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Mr Liam Acheson (PhD student)	A/Prof Nadine Ezard (Director)	National Centre for Clinical Research on Emerging Drugs
Mr Liam Acheson (PhD student)	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Mr Jack Freestone (PhD student)	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Mr Oliver Harris (Medicine Hons student)	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Ms Rhiannon Lindsey (Medicine student)	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Ms Amy Healey (ILP student)	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Mr Keaton Buhagiar	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs
Mr Vincent Chauvet	Dr Krista Siefried (Deputy Director)	National Centre for Clinical Research on Emerging Drugs